1
EXHIBIT 10.37
--------------------------------------------------------------------------------
AGREEMENT AND PLAN OF MERGER
BY AND AMONG
--------------------------------------------------------------------------------
ACCUMED INTERNATIONAL, INC.,
ACCUMED ACQUISITION CORP.
AND
AMPERSAND MEDICAL CORPORATION
DATED AS OF FEBRUARY 7, 2001
2
TABLE OF CONTENTS
--------------------------------------------------------------------------------
ARTICLE I THE MERGER AND RELATED MATTERS......................................................................2
1.1 Merger....................................................................................2
1.2 Merger Effective Time.....................................................................2
1.3 Conversion of Shares......................................................................2
1.4 Surviving Corporation in the Merger.......................................................4
1.5 Authorization for Issuance of Ampersand Common Stock; Exchange of Certificates............5
1.6 No Fractional Shares......................................................................6
1.7 Stockholder Approvals.....................................................................7
1.8 AccuMed Stock Options.....................................................................7
1.9 Registration Statement; Prospectus/Proxy Statement........................................7
1.10 Cooperation; Regulatory Approvals.........................................................8
1.11 Closing...................................................................................9
1.12 Ampersand Loan to AccuMed.................................................................9
ARTICLE II REPRESENTATIONS AND WARRANTIES.....................................................................11
2.1 Organization, Good Standing, Authority, Insurance, Etc...................................11
2.2 Capitalization...........................................................................11
2.3 Ownership of Subsidiaries................................................................12
2.4 Financial Statements and Reports.........................................................12
2.5 Absence of Changes.......................................................................13
2.6 Prospectus/Proxy Statement...............................................................14
2.7 No Broker's or Finder's Fees.............................................................14
2.8 Litigation and Other Proceedings.........................................................14
2.9 Compliance with Law......................................................................14
2.10 Corporate Actions........................................................................15
2.11 Authority................................................................................15
2.12 Employment Arrangements..................................................................16
2.13 Employee Benefits........................................................................16
2.14 Information Furnished....................................................................17
2.15 Property and Assets......................................................................17
2.16 Agreements and Instruments...............................................................18
2.17 Material Contract Default; Contingent Liabilities........................................18
2.18 Tax Matters..............................................................................19
2.19 Environmental Matters....................................................................19
2.20 Exceptions to Representations and Warranties.............................................20
i
3
ARTICLE III COVENANTS..........................................................................................20
3.1 Investigations; Access and Copies........................................................20
3.2 Conduct of Business......................................................................21
3.3 No Solicitation..........................................................................23
3.4 Stockholder Approvals....................................................................23
3.5 Accounting and Tax Treatment.............................................................23
3.6 Publicity................................................................................24
3.7 Cooperation Generally....................................................................24
3.8 Additional Financial Statements and Reports..............................................24
3.9 Employee Benefits and Agreements.........................................................24
3.10 Ampersand Lock-Up Agreements.............................................................25
ARTICLE IV CONDITIONS OF THE MERGER; TERMINATION OF AGREEMENT.................................................25
4.1 Conditions to the Obligations of Each Party..............................................25
4.2 Conditions to Obligations of AccuMed.....................................................28
4.3 Conditions to Obligations of Ampersand and Acquisition Sub...............................28
4.4 Termination of Agreement.................................................................30
ARTICLE V TERMINATION OBLIGATIONS............................................................................32
5.1 Breach by AccuMed........................................................................32
5.2 Breach by Ampersand......................................................................32
5.3 Tender or Exchange Offer.................................................................32
5.4 Non-Fulfillment of AccuMed Obligations...................................................32
5.5 Payment of Replacement Note..............................................................33
ARTICLE VI CERTAIN POST-MERGER AGREEMENTS.....................................................................33
6.1 Indemnification..........................................................................33
ARTICLE VII GENERAL............................................................................................34
7.1 Amendments...............................................................................34
7.2 Confidentiality..........................................................................35
7.3 Governing Law............................................................................35
7.4 Notices..................................................................................35
7.5 No Assignment............................................................................36
7.6 Headings.................................................................................36
7.7 Counterparts.............................................................................36
7.8 Construction and Interpretation..........................................................37
7.9 Binding Effect...........................................................................37
7.10 Expenses. ..............................................................................37
7.11 Third Parties. .........................................................................37
7.12 Entire Agreement. ......................................................................37
7.13 Waivers. ...............................................................................37
7.14 Partial Invalidity. ....................................................................37
ii
4
Schedules:
Schedule I Disclosure Schedules for AccuMed
Schedule II Disclosure Schedules for Ampersand and Acquisition Sub
Exhibits:
Exhibit A Form of AccuMed Voting Agreement
Exhibit B Form of Replacement Note
Exhibit C Budget Statement
Exhibit D List of Employees Whose Employment Agreements Will Be
Terminated
Exhibit E Certificate of Designation, Preferences and Rights of
Series A Convertible Preferred Stock of Ampersand
Exhibit F Revised Budget Statement
iii
5
AGREEMENT AND PLAN OF MERGER
THIS AGREEMENT AND PLAN OF MERGER ("Agreement") is made and entered into as
of February 7, 2001 (the "Execution Date"), by and among AccuMed International,
Inc., a Delaware corporation ("AccuMed"), AccuMed Acquisition Corp., a Delaware
corporation ("Acquisition Sub"), and Ampersand Medical Corporation, a Delaware
corporation ("Ampersand").
RECITALS
WHEREAS, as of the execution hereof, AccuMed has (i) 50,000,000 authorized
shares of common stock, $.01 par value (the "AccuMed Common Stock"), of which
5,733,935 shares are currently issued and outstanding, and (ii) 5,000,000
authorized shares of preferred stock, of which 581,339 shares of Series A
Convertible Preferred Stock, $.01 par value (the "AccuMed Preferred Stock"), are
currently issued and outstanding and convertible into 387,562 shares of AccuMed
Common Stock; and
WHEREAS, as of the execution hereof, Ampersand has (i) 50,000,000
authorized shares of common stock, $.001 par value (the "Ampersand Common
Stock"), of which 30,056,468 shares are currently issued and outstanding, and
(ii) 5,000,000 authorized shares of preferred stock, none of which are currently
issued and outstanding; and
WHEREAS, as of the execution hereof, Acquisition Sub has 3,000 authorized
shares of common stock, without par value (the "Acquisition Sub Common Stock"),
of which 100 shares are currently issued and outstanding and owned by Ampersand;
and
WHEREAS, the parties hereto desire that AccuMed be merged with and into
Acquisition Sub in accordance with the terms and provisions of this Agreement,
with Acquisition Sub as the surviving corporation (such merger being referred to
hereinafter as the "Merger," and Acquisition Sub, after the Merger, being
sometimes referred to hereinafter as the "Surviving Corporation"); and
WHEREAS, it is intended that for federal income tax purposes the Merger
shall qualify as a reorganization within the meaning of Section 368 of the
Internal Revenue Code of 1986, as amended (the "Internal Revenue Code"), and
this Agreement shall constitute a plan of reorganization pursuant to Section 368
of the Internal Revenue Code; and
WHEREAS, concurrently with the execution and delivery of this Agreement,
and as an inducement to and condition of the willingness of Ampersand and
Acquisition Sub to enter into
1
6
this Agreement, each of the persons who are currently officers and/or directors
of AccuMed have entered into voting agreements in the form attached hereto as
Exhibit A; and
WHEREAS, the Board of Directors of each of the parties hereto, at meetings
duly called and held, or pursuant to informal actions taken in accordance with
applicable law, have determined that this Agreement and the transactions
contemplated thereby are in the best interests of the respective parties, and
the Board of Directors of each of AccuMed and Acquisition Sub have determined to
recommend to their respective stockholders that they approve this Agreement and
the transactions contemplated thereby;
NOW, THEREFORE, in consideration of the premises and the representations,
warranties, covenants and agreements hereinafter set forth, the parties hereto
hereby agree as follows:
ARTICLE I
THE MERGER AND RELATED MATTERS
I Merger. Subject to the terms and conditions of this Agreement and
pursuant to applicable law, at the Merger Effective Time (as such term is
hereinafter defined), (i) AccuMed shall be merged with and into Acquisition Sub,
(ii) the separate corporate existence of AccuMed shall cease, and (iii)
Acquisition Sub, which shall immediately change its name to "AccuMed
International, Inc.", as the Surviving Corporation, shall continue to be
governed by the laws of the State of Delaware.
II Merger Effective Time. As soon as practicable after each of the
conditions set forth in Article IV hereof has been satisfied or waived, the
parties hereto will file, or cause to be filed, a certificate of merger with the
appropriate authorities of the State of Delaware for the Merger, which
certificate of merger shall be in the form required by and executed in
accordance with the applicable provisions of law. The Merger shall become
effective at the time and date that the Delaware certificate of merger is filed
with the appropriate authorities of the State of Delaware (the "Merger Effective
Time"), which shall be immediately following the Closing (as such term is
hereinafter defined) and on the same day as the Closing, if practicable, or at
such other date and time as may be agreed to by the parties and specified in the
certificate of merger in accordance with applicable law.
III Conversion of Shares. At the Merger Effective Time, by virtue of the
Merger and without any action on the part of the parties hereto or the holders
of shares of AccuMed Common Stock, AccuMed Preferred Stock, Ampersand Common
Stock or Acquisition Sub Common Stock:
I Each share of AccuMed Common Stock issued and outstanding at the
Merger Effective Time (except for Dissenting Shares, if applicable, as defined
in Section 1.3(b)
2
7
hereof), subject to Sections 1.3 (e) and 1.6 hereof, shall cease to be
outstanding, shall cease to exist and shall be converted into and become six
thousand five hundred fifty-two ten thousandths (.6552) of one (1) share of
Ampersand Common Stock, which ratio (the "Exchange Ratio") shall be reduced if
any AccuMed Derivative Securities (as defined in Section 1.3(c) hereof) are
exchanged for or converted into shares of AccuMed Common Stock between the
Execution Date and the Merger Effective Time such that four million (4,000,000)
shares of Ampersand Common Stock will be, in the aggregate, (i) exchanged for
the AccuMed Common Stock, and/or (ii) reserved for issuance upon future
conversion of shares of Ampersand Preferred Stock (as such term is hereinafter
defined) into shares of Ampersand Common Stock.
II Each share of AccuMed Preferred Stock issued and outstanding at the
Merger Effective Time (except for Dissenting Shares, if applicable), subject to
Sections 1.3(e) and 1.6 hereof shall also cease to be outstanding, shall also
cease to exist and shall be converted into and become one (1) share of Ampersand
Series A Convertible Preferred Stock (the "Ampersand Preferred Stock"), which
shall have the rights and preferences set forth in the Certificate of
Designation, Preferences and Rights of Series A Convertible Preferred Stock
attached hereto as Exhibit E, including, but not limited to, the right to be
converted into shares of Ampersand Common Stock in accordance with the Exchange
Ratio.
III Any shares of AccuMed capital stock held by a holder who dissents
from the Merger in accordance with Section 262 of the Delaware General
Corporation Law (the "DGCL") shall be referred to herein as "Dissenting Shares."
Notwithstanding any other provision of this Agreement, any Dissenting Shares
shall not, after the Merger Effective Time, be entitled to vote for any purpose
or receive any dividends or other distributions and shall be entitled only to
such rights as are afforded with respect to Dissenting Shares pursuant to the
DGCL.
4 Every AccuMed security, except shares of AccuMed Preferred Stock,
issued and outstanding at the Execution Date that is convertible into,
exchangeable for or exerciseable with respect to, shares of AccuMed Common
Stock, including all stock options, warrants and convertible debt instruments
(collectively, the "AccuMed Derivative Securities"), if not converted, exchanged
or exercised prior to the Merger Effective Time, shall, from and after the
Merger Effective Time, be instead convertible into, exchangeable for or
exerciseable with respect to Ampersand Common Stock at the Exchange Ratio upon
payment of the applicable consideration required in connection with such
conversion, exercise or exchange. The foregoing substitutions shall be
undertaken consistent with, and not in a manner that will constitute a
"modification" under, Section 424 of the Internal Revenue Code with respect to
any such stock option that is an "incentive stock option." Furthermore,
Ampersand shall make all filings required under federal and state securities
laws promptly after the Merger Effective Time so as to permit the conversion,
exchange or exercise of any such AccuMed Derivative Securities, and the sale of
the shares of Ampersand Common Stock received by the security holder upon such
conversion, exchange or exercise at and after the Merger Effective Time, and
Ampersand shall continue to make such
3
8
filings thereafter as may be necessary to permit the continued conversion,
exchange or exercise of such securities and sale of such shares.
IV Any AccuMed securities that are owned or held by any party hereto
(other than in a fiduciary capacity) at the Merger Effective Time shall cease to
exist, the certificates for such securities shall as promptly as practicable be
cancelled, such securities shall not be converted into or evidence any
securities of Ampersand Common Stock, and no shares of capital stock of
Ampersand shall be issued or exchanged therefor.
V Each share of Ampersand Common Stock issued and outstanding
immediately before the Merger Effective Time shall remain an outstanding share
of Ampersand Common Stock after the Merger Effective Time, and each share of
Acquisition Sub Common Stock issued and outstanding immediately before the
Merger Effective Time shall remain an outstanding share of Acquisition Sub
Common Stock after the Merger Effective Time.
VI The holders of certificates evidencing shares of AccuMed Common
Stock, AccuMed Preferred Stock or any other securities of AccuMed shall
thereafter have no rights as stockholders of AccuMed (or Acquisition Sub),
except such rights, if any, as they may have pursuant to the DGCL.
IV Surviving Corporation in the Merger.
I The name of the Surviving Corporation in the Merger shall be
changed from "AccuMed Acquisition Corp." to "AccuMed International, Inc."
II At the Merger Effective Time, subject to an amendment to change
the name of the Surviving Corporation in accordance with the provisions of
Section 1.4(a) hereof, the Certificate of Incorporation of Acquisition Sub as
then in effect shall be the Certificate of Incorporation of the Surviving
Corporation until further amended as provided therein or as otherwise permitted
by the DGCL.
III At the Merger Effective Time, the Bylaws of Acquisition Sub as
then in effect shall be the Bylaws of the Surviving Corporation until amended as
provided therein or as otherwise permitted by the DGCL.
IV The directors and executive officers of Acquisition Sub as of the
Merger Effective Time shall remain as the directors and officers of the
Surviving Corporation following the Merger until such directors or officers are
replaced or additional directors or officers are elected or appointed in
accordance with the provisions of the Certificate of Incorporation and Bylaws of
the Surviving Corporation.
4
9
V From and after the Merger Effective Time:
I Acquisition Sub as the Surviving Corporation shall possess all
assets and property of every description, and every interest in the assets and
property, wherever located, and the rights, privileges, immunities, powers,
franchises and authority, of a public as well as of a private nature, of each of
AccuMed and Acquisition Sub, and all obligations belonging or due to each of
AccuMed and Acquisition Sub, all of which shall vest in the Surviving
Corporation without further act or deed. Title to any real estate or any
interest in real estate vested in AccuMed or Acquisition Sub shall not revert
nor in any way be impaired by reason of the Merger.
II The Surviving Corporation will be liable for all of the
obligations of each of AccuMed and Acquisition Sub. Any claim existing, or
action or proceeding pending, by or against AccuMed or Acquisition Sub, may be
prosecuted to judgment, with right of appeal, as if the Merger had not taken
place, and the Surviving Corporation may be substituted in its place.
III All of the rights of creditors of each of AccuMed and
Acquisition Sub will be preserved unimpaired, and all of the liens upon the
property of AccuMed and Acquisition Sub will be preserved unimpaired only on the
property affected by such liens immediately before the Merger Effective Time.
V Authorization for Issuance of Ampersand Common Stock; Exchange of
Certificates.
I Ampersand shall reserve for issuance a sufficient number of
shares of Ampersand Common Stock for the purpose of issuing such shares to (i)
the former holders of AccuMed Common Stock and AccuMed Preferred Stock, and (ii)
the holders of AccuMed Derivative Securities, all in accordance with this
Article I.
II After the Merger Effective Time, holders of certificates
theretofore evidencing outstanding AccuMed securities (other than as provided in
Section 1.3 hereof), upon surrender of such certificates to an exchange agent
appointed by Ampersand (the "Exchange Agent"), shall be entitled to receive
certificates for the Ampersand securities to be substituted for the aforesaid
AccuMed securities in accordance with the provisions of Section 1.3 hereof, and
cash payments in lieu of fractional shares, if any, as provided in Section 1.6
hereof. As soon as practicable after the Merger Effective Time, the Exchange
Agent will send a notice and transmittal form to each record holder of AccuMed
securities at the Merger Effective Time whose securities are being exchanged in
the manner provided herein, advising such holder of the effectiveness of the
Merger and the procedure for surrendering to the Exchange Agent outstanding
certificates formerly evidencing AccuMed securities in exchange for new
certificates evidencing the substituted Ampersand securities. Upon surrender,
each certificate formerly evidencing AccuMed securities shall be cancelled.
5
10
III Until surrendered as provided in this Section 1.5, all
outstanding certificates of a holder which, before the Merger Effective Time,
evidenced AccuMed securities (other than those evidencing Dissenting Shares and
shares cancelled at the Merger Effective Time pursuant to Section 1.3 hereof)
will be deemed for all corporate purposes to evidence the securities of
Ampersand exchanged for the AccuMed securities formerly evidenced thereby and
the right to receive cash in lieu of any fractional Ampersand Common Stock
interests the holder might otherwise have been entitled to receive hereunder.
However, until such outstanding certificates formerly evidencing AccuMed
securities are so surrendered, no dividend or distribution payable to holders of
record of Ampersand Common Stock shall be paid to any holder of such outstanding
certificates, but upon surrender of such outstanding certificates by such holder
there shall be paid to such holder the amount of any dividends or distribution,
without interest, theretofore paid with respect to such shares of Ampersand
Common Stock, but not paid to such holder, and which dividends or distribution
had a record date occurring on or after the Merger Effective Time and the amount
of any cash, without interest, payable to such holder in lieu of a fractional
share interest pursuant to Section 1.6 hereof. After the Merger Effective Time,
there shall be no further registration of transfers on the records of AccuMed of
outstanding certificates formerly evidencing AccuMed securities and, if a
certificate formerly evidencing such securities is presented to any party
hereto, it shall be forwarded to the Exchange Agent for cancellation and
exchanged for a certificate evidencing Ampersand securities and cash for any
Ampersand Common Stock interests the holder might otherwise have been entitled
to receive hereunder as herein provided. Following six (6) months after the
Merger Effective Time, the Exchange Agent shall return to Ampersand any
certificates for Ampersand securities and cash remaining in the possession of
the Exchange Agent (together with any dividends in respect thereof) and
thereafter the former holders of AccuMed securities shall look exclusively to
Ampersand for Ampersand securities and cash to which they may be entitled
hereunder.
IV All securities and cash in lieu of any fractional shares issued
or paid upon the exchange of AccuMed securities in accordance with the above
terms and conditions shall be deemed to have been issued or paid in full
satisfaction of all rights pertaining to such AccuMed securities.
V If any new certificate for Ampersand securities is to be issued
in a name other than that in which the certificate surrendered in exchange
therefor is registered, it shall be a condition of the issuance therefor that
the certificate surrendered in exchange shall be properly endorsed and otherwise
in proper form for transfer and that the person requesting such transfer pay to
the Exchange Agent any transfer or other taxes required by reason of the
issuance of a new certificate evidencing Ampersand securities in any name other
than that of the registered holder of the certificate surrendered, or establish
to the satisfaction of the Exchange Agent that such tax has been paid or is not
payable.
6
11
VI In the event that any certificate evidencing AccuMed securities
shall have been lost, stolen or destroyed, the Exchange Agent shall issue in
exchange for such lost, stolen or destroyed certificate, upon the making of an
affidavit of that fact by the holder thereof, such Ampersand securities and cash
for any fractional share interest as may be required pursuant hereto; provided,
however, that Ampersand, the Surviving Corporation or the Exchange Agent may, in
the discretion of any of them, and as a condition precedent to the issuance or
payment thereof, require the owner of such lost, stolen or destroyed certificate
to deliver a bond in such sum as the requesting party may direct as indemnity
against any claim that may be made against Ampersand, the Surviving Corporation,
AccuMed, the Exchange Agent or any other person with respect to the certificate
alleged to have been lost, stolen or destroyed.
VI No Fractional Shares. Notwithstanding any term or provision hereof, no
fractional shares of Ampersand Common Stock, and no certificates or scrip
therefor, or other evidence of ownership thereof, will be issued upon the
conversion of or in exchange for any AccuMed securities; no dividend or
distribution with respect to Ampersand Common Stock shall be payable on or with
respect to any fractional share interest; and no such fractional share interest
shall entitle the owner thereof to vote or to any other rights of a stockholder
of Ampersand or the Surviving Corporation. In lieu of such fractional share
interest, any holder of AccuMed securities who would otherwise be entitled to a
fractional share of Ampersand Common Stock will, upon surrender of such holder's
certificate or certificates evidencing AccuMed Common securities outstanding
immediately before the Merger Effective Time, be paid the applicable cash value
of such fractional share interest, which shall be equal to the product of the
fraction of the share to which such holder would otherwise have been entitled
and the closing price of Ampersand Common Stock on the trading day immediately
prior to the date of the Merger Effective Time. For the purpose of determining
any such fractional share interest, all AccuMed securities owned by a holder of
AccuMed Common Stock shall be considered in the aggregate so as to calculate the
maximum number of whole shares of Ampersand Common Stock issuable to such
person.
VII Stockholder Approvals.
I AccuMed shall, at the earliest practicable date, but in no event
later than forty-five (45) days after the effective date of the Registration
Statement (as such term is defined in Section 1.9(a) hereof), hold a meeting of
its stockholders (the "AccuMed Stockholders' Meeting") to submit this Agreement
for adoption by its stockholders. The affirmative vote of that number of holders
of outstanding shares of AccuMed capital stock entitled to vote on such matter
pursuant to the provisions of AccuMed's Certificate of Incorporation and the
DGCL shall be required for such adoption.
II Ampersand, as the sole shareholder of Acquisition Sub, shall, at
the earliest practicable date, but in no event later than the date on which the
AccuMed Stockholders' Meeting
7
12
is held, by informal action in accordance with the provisions of the DGCL, cause
this Agreement to be adopted on behalf of Acquisition Sub.
VIII AccuMed Stock Options.
At the Merger Effective Time, by virtue of the Merger and without any
action on the part of any holder of an option, each outstanding option under the
stock option plans of AccuMed, in existence at the Execution Date, whether
vested or unvested, shall continue outstanding as an option to purchase, in
place of the purchase of each share of AccuMed Common Stock, the number of
shares of Ampersand Common Stock as shall be determined by the Exchange Ratio.
IX Registration Statement; Prospectus/Proxy Statement.
I For the purposes (i) of holding the AccuMed Stockholders' Meeting,
and (ii) of registering with the Securities and Exchange Commission ("SEC") and
with applicable state securities authorities the Ampersand Common Stock to be
issued to holders of AccuMed securities in connection with the Merger, the
parties shall cooperate in the preparation of an appropriate registration
statement (such registration statement, together with all and any amendments and
supplements thereto, is referred to herein as the "Registration Statement"),
including the Prospectus /Proxy Statement satisfying all applicable requirements
of applicable state laws, and of the Securities Act of 1933, as amended (the
"Securities Act"), and the Securities Exchange Act of 1934, as amended (the
"Exchange Act"), and the rules and regulations thereunder (such Prospectus/Proxy
Statement, together with any and all amendments or supplements thereto, is
referred to herein as the "Prospectus/Proxy Statement").
II AccuMed shall furnish such information concerning AccuMed as is
necessary in order to cause the Prospectus/Proxy Statement, insofar as it
relates to AccuMed, to comply with Section 1.9(a) hereof. AccuMed agrees
promptly to advise Ampersand if at any time before the AccuMed Stockholders'
Meeting any information provided by AccuMed in the Prospectus/Proxy Statement
becomes incorrect or incomplete in any material respect and to provide the
information needed to correct such inaccuracy or omission. AccuMed shall also
furnish Ampersand with such supplemental information as may be necessary in
order to cause such Prospectus/Proxy Statement, insofar as it relates to
AccuMed, to comply with Section 1.9(a) hereof.
III Ampersand and Acquisition Sub shall furnish AccuMed with such
information concerning Ampersand as is necessary in order to cause the
Prospectus/Proxy Statement, insofar as it relates to Ampersand and Acquisition
Sub, to comply with Section 1.9(a) hereof. Ampersand and Acquisition Sub agree
promptly to advise AccuMed if at any time before the AccuMed Stockholders'
Meeting any information provided by Ampersand in the
8
13
Prospectus/Proxy Statement becomes incorrect or incomplete in any material
respect and to provide AccuMed with the information needed to correct such
inaccuracy or omission. Ampersand and Acquisition Sub shall furnish AccuMed with
such supplemental information as may be necessary in order to cause the
Prospectus/Proxy Statement, insofar as it relates to Ampersand and Acquisition
Sub, to comply with Section 1.9(a).
IV Ampersand shall promptly file with the SEC and applicable state
securities agencies the Registration Statement and all supplements or amendments
thereto that shall become necessary as a result of information covered by the
provisions of Sections 1.9(b) and (c) coming to the attention of Ampersand. The
parties hereto shall use all reasonable efforts to cause the Registration
Statement to become effective under the Securities Act and applicable state
securities laws at the earliest practicable date. AccuMed authorizes Ampersand
to utilize in the Registration Statement the information provided by AccuMed in
regard to itself for the purpose of inclusion in the Prospectus/Proxy Statement.
Ampersand shall advise AccuMed promptly when the Registration Statement has
become effective and of any supplements or amendments thereto, and Ampersand
shall furnish AccuMed with copies of all such documents. Before the Merger
Effective Time or the termination of this Agreement, each party shall consult
with the other with respect to any material (other than the Prospectus/Proxy
Statement) that might constitute a "prospectus" relating to the Merger within
the meaning of the Securities Act.
X Cooperation; Regulatory Approvals. The parties shall cooperate, and
shall cause each of their respective affiliates to cooperate, in the preparation
and submission by them, as promptly as reasonably practicable, of such
applications, petitions and other filings as either of them may reasonably deem
necessary or desirable to or with (i) all regulatory or governmental authorities
having jurisdiction in regard to the Merger, (ii) the holders of shares of
AccuMed securities, and (iii) any other persons, for the purpose of obtaining
any approvals or consents necessary to consummate the Merger and the
transactions contemplated hereby. Each party will have the right to review and
comment on such applications, petitions and filings in advance and shall furnish
to the other copies thereof promptly after submission thereof. Any such
materials must be acceptable to each of the parties hereto prior to submission
to any regulatory or governmental authority or to any security holders or other
third parties, except to the extent that the parties hereto may be legally
required to proceed prior to obtaining such acceptance of the other parties
hereto. Each party agrees to consult with the others with respect to obtaining
all necessary consents and approvals, and each will keep the others apprised of
the status of matters relating to such approvals and consents and the
consummation of the transactions contemplated hereby. At the date hereof, none
of the parties is aware of any reason that any regulatory approval required to
be obtained by it would not be obtained or would be obtained subject to
conditions that would have or result in a material adverse effect on any of the
parties hereto.
XI Closing. If (i) this Agreement has been duly approved by the
respective stockholders of AccuMed and Acquisition Sub, and (ii) all relevant
conditions of this Agreement
9
14
have been satisfied or waived, a closing (the "Closing") shall take place as
promptly as practicable thereafter at the principal office of Schwartz, Cooper,
Xxxxxxxxxxx & Xxxxxx, Chartered, Chicago, Illinois, or at such other place as
the parties agree upon, at which the parties will exchange certificates,
opinions, letters and other documents as required hereby and will make the
filings described in Section 1.2 hereof. Such Closing will take place within
five (5) business days after the satisfaction or waiver of all conditions and/or
obligations precedent to Closing contained in Article IV hereof, or at such
other time as the parties agree upon. The parties shall use their respective
best efforts to cause the Closing to occur on or prior to May 31, 2001 (the date
of such Closing being hereinafter sometimes referred to as the "Closing Date").
XII Ampersand Loan to AccuMed. (a) The parties acknowledge and agree that
upon execution of this Agreement by the parties, and as an additional inducement
to AccuMed's acceptance of this Agreement and its covenant to enter into and
consummate the Merger, Ampersand shall make a loan to AccuMed in the aggregate
principal amount of Eight Hundred Thousand Dollars ($800,000) (the "Full Loan"),
in immediately available funds, of which Three Hundred Thousand Dollars
($300,000) (the "Interim Loan") was previously advanced by Ampersand to AccuMed
on September 22, 2000, as evidenced by a certain promissory note of said date
issued by AccuMed to Ampersand (the "Initial Note"). The Full Loan shall be
evidenced by AccuMed's delivery to Ampersand, at the Execution Date, of a new
promissory note (the "Replacement Note") substantially in the form of Exhibit B
attached hereto, which instrument shall replace the Initial Note and provide,
among other things, for repayment of the full Eight Hundred Thousand Dollars
($800,000) of principal, with interest at the Prime Rate from time to time
announced by LaSalle Bank National Association, plus two and one-half percent (2
1/2 %). The Replacement Note shall be secured by the grant of a first perfected
security interest in, and lien against, the applicable collateral described in
that certain Security Agreement, dated contemporaneously herewith, by and
between AccuMed, as debtor thereunder, and Ampersand, as secured party
thereunder (the "Security Agreement"). In addition to the foregoing, Ampersand
and AccuMed agreed that the making of the Full Loan to AccuMed would be
specifically conditioned upon the delivery by AccuMed to Ampersand of (i) a
budget and projected cash flow statement (the "Budget Statement") for the six
(6) month period commencing on September 22, 2000, which Budget Statement would
be satisfactory to Ampersand in all respects, in Ampersand's sole discretion,
and the parties hereto acknowledge and agree that such Budget Statement has
heretofore been delivered by AccuMed to Ampersand, and that such Budget
Statement (a copy of which is attached hereto as Exhibit C) has been determined
by Ampersand to be satisfactory, and (ii) a revised budget (the "Revised Budget
Statement") for the period from and after the Execution Date and until the
anticipated date of closing hereunder which sets forth the use of proceeds from
the Full Loan and any Additional Loans (as such term is hereinafter defined) by
AccuMed during such period and within which AccuMed will operate and not deviate
from without the prior written consent of Ampersand, not to be unreasonably
withheld (a copy of which Revised Budget Statement is attached hereto as Exhibit
F).
10
15
(b) Ampersand and AccuMed also hereby agree that (i) if by February
28, 2001 the Merger and the transactions contemplated hereby have not been
consummated, then on the first day of each month thereafter, through May 31,
2001, Ampersand shall loan to AccuMed an additional Two Hundred Twenty-Five
Thousand Dollars ($225,000) (the "Additional Loans") on the same terms and
conditions as the Full Loan, provided that, simultaneously with the making of
each Additional Loan, (1) the collateral securing the Full Loan under the
Security Agreement shall be increased in accordance with the terms of the
Security Agreement in order to secure such Additional Loan as well, and (2)
AccuMed shall issue and deliver to Ampersand a new promissory note,
substantially in the form of the Replacement Note, evidencing such Additional
Loan; and (ii) if by May 31, 2001, the Merger and the transactions contemplated
hereby have not been consummated, but the parties hereto have mutually agreed to
extend the May 31, 2001 deadline contained in Section 4.4 hereof for effecting
the Merger and consummating such transactions, then the time period in which
Ampersand shall be obligated to make such monthly Additional Loans (in the same
amount and on the same terms and conditions) shall be automatically extended
until the Merger and the transactions contemplated hereby are consummated, or
this Agreement is terminated, whichever comes first; provided, however, that
prior to the making of each Additional Loan during such extended period, AccuMed
and Ampersand shall identify on a schedule or schedules to be attached to the
Security Agreement sufficient additional collateral to secure such Additional
Loans in accordance with the terms and conditions of the Security Agreement.
Each Additional Loan shall be made by wire transfer in immediately available
funds to a bank account specified in writing by AccuMed for such purpose. If the
first day of a month on which an Additional Loan is required to be made
hereunder occurs on a Saturday, Sunday or bank holiday in the State of Illinois,
such Additional Loan shall be made on the immediately preceding date which is
not a Saturday, Sunday or bank holiday. The parties hereto specifically
acknowledge and agree that the failure of Ampersand to make any Additional Loan
within five (5) banking days after the date on which such Additional Loan is
required to be made hereunder shall be an event of default hereunder, entitling
AccuMed to terminate this Agreement immediately upon delivery of written notice
thereof in accordance with the notice provisions of this Agreement.
ARTICLE II
REPRESENTATIONS AND WARRANTIES
AccuMed hereby represents and warrants to Ampersand and Acquisition Sub,
and Ampersand and Acquisition Sub hereby jointly and severally represent and
warrant to AccuMed, except as disclosed in the Disclosure Schedules delivered by
each of the parties to the others pursuant to Section 2.20 hereof, as follows:
I Organization, Good Standing, Authority, Insurance, Etc. It is a
corporation duly organized, validly existing and in good standing under the laws
of the jurisdiction of its incorporation. Section 2.1 of its Disclosure
Schedules lists each "subsidiary" (the term
11
16
"subsidiary" when used with respect to any party means any entity (including,
without limitation, any corporation, partnership, joint venture or other
organization, whether incorporated or unincorporated) which is consolidated with
such party for financial reporting purposes (individually a "Subsidiary" and
collectively the "Subsidiaries"). Each of its Subsidiaries is duly organized,
validly existing and in good standing under the laws of the jurisdiction under
which it is organized, as set forth in Section 2.1 of its Disclosure Schedules.
It and each of its Subsidiaries has all requisite power and authority, and to
the extent required by applicable law, is licensed to own, lease and operate its
own properties and conduct its business as now being conducted. It has delivered
or made available to the other parties a true, complete and correct copy of the
articles of incorporation, certificate of incorporation or other organizing
document and of the bylaws, as in effect on the date of this Agreement, of it
and each of its Subsidiaries. Except as set forth in Section 2.1 of its
Disclosure Schedules, it and each of its Subsidiaries is qualified to do
business as a foreign corporation or entity and is in good standing in each
jurisdiction in which qualification is necessary under applicable law, except to
the extent that any failures to so qualify would not, in the aggregate, have a
material adverse effect on it. Its minute books and those of each of its
Subsidiaries contain complete and accurate records of all meetings and other
corporate actions taken by its stockholders and Boards of Directors (including
the committees of such Boards).
II Capitalization.
I Its authorized capital stock and the number of issued and
outstanding shares of its capital stock as of the date hereof are accurately set
forth in the recitals to this Agreement. All outstanding shares of its common
stock are duly authorized, validly issued, fully paid, nonassessable and free of
preemptive rights. Except as set forth in Section 2.2 of its Disclosure
Schedules, as of the date of this Agreement, there are no options, convertible
securities, warrants or other rights (preemptive or otherwise) to purchase or
acquire any of its capital stock from it and no oral or written agreement,
contract, arrangement, understanding, plan or instrument of any kind to which it
or any of its Subsidiaries is subject with respect to the issuance, voting or
sale of issued or unissued shares of its capital stock, and, with respect to any
such securities or rights disclosed by Ampersand, Ampersand represents and
warrants that there are no agreements with respect to such securities or rights,
and no terms or provisions of or relating to such securities or rights, the
effect of which would be to reduce the exercise price at which such securities
or rights may be converted into shares of Ampersand Common Stock as a
consequence of consummating the Merger or the transactions contemplated hereby.
A true and complete copy of each plan and agreement pursuant to which such
options, convertible securities, warrants or other rights have been granted or
issued, as in effect on the date of this Agreement, is included in Section 2.2
of its Disclosure Schedules. Only the holders of its common stock have the right
to vote at meetings of its stockholders on matters to be voted on thereat,
except that the holders of shares of AccuMed Preferred Stock possess the right
to vote on certain matters affecting the rights of such holders. The securities
of AccuMed held in AccuMed's corporate treasury are identified in Section 2.2 of
AccuMed's Disclosure Schedules.
12
17
II With respect to the shares of Ampersand Common Stock to be issued
in the Merger, Ampersand represents and warrants that such shares when so issued
in accordance with this Agreement will be duly authorized, validly issued, fully
paid and nonassessable and not subject to any preemptive rights.
III Ownership of Subsidiaries. All outstanding shares or ownership
interests of its Subsidiaries are validly issued, fully paid, nonassessable and
owned beneficially and of record by it or one of its Subsidiaries, free and
clear of any lien, claim, charge, restriction, rights of third parties or
encumbrance (collectively, "Encumbrance"), except as set forth in Section 2.3 of
its Disclosure Schedules. There are no options, convertible securities, warrants
or other rights (preemptive or otherwise) to purchase or acquire any capital
stock or ownership interests of any of its Subsidiaries and no contracts to
which it or any of its Subsidiaries is subject with respect to the issuance,
voting or sale of issued or unissued shares of the capital stock or ownership
interests of any of its Subsidiaries. Neither it nor any of its Subsidiaries
owns more than two percent (2%) of the capital stock or other equity securities
(including securities convertible or exchangeable into such securities) of, or
more than two percent (2%) of the aggregate profit participations in, any entity
other than a Subsidiary or as otherwise set forth in Section 2.3 of its
Disclosure Schedules.
IV Financial Statements and Reports. With respect to Ampersand and
AccuMed:
I No registration statement, offering circular, proxy statement,
schedule or report filed by it or any of its Subsidiaries under various
securities laws and regulations ("Regulatory Reports"), on the date of its
effectiveness in the case of such registration statements, or on the date of
filing in the case of such reports or schedules, or on the date of mailing in
the case of such proxy statements, contained any untrue statement of a material
fact or omitted to state a material fact required to be stated therein or
necessary to make the statements therein, in light of the circumstances under
which they were made, not misleading. For the past five years, it and its
Subsidiaries have timely filed all Regulatory Reports required to be filed by
them under various securities laws and regulations, except to the extent that
all failures to so file, in the aggregate, would not have a material adverse
effect on it; and all such documents, as finally amended, complied in all
material respects with applicable requirements of law and, as of their
respective dates or the dates as amended, did not contain any untrue statement
of a material fact or omit to state a material fact required to be stated
therein or necessary to make the statements therein, in light of the
circumstances under which they were made, not misleading. Except to the extent
stated therein, all financial statements and schedules included in the
Regulatory Reports (or to be included in Regulatory Reports to be filed after
the date hereof) (i) are or will be (with respect to financial statements with
respect to periods ending after September 30, 2000), in accordance with its
books and records and those of its consolidated Subsidiaries, and (ii) present
(and in the case of financial statements with respect to periods ending after
September 30, 2000, will present) fairly the consolidated financial position and
consolidated results of operations or income, changes in the
13
18
consolidated stockholders' equity and cash flows of it and its Subsidiaries as
of the dates and for the periods indicated in accordance with generally accepted
accounting principles applied on a basis consistent with prior periods (except
for the omission of notes to unaudited statements and in the case of unaudited
statements to normal recurring year-end adjustments normal in nature and
amounts). Its audited consolidated financial statements at December 31, 1999 and
for the year then ended and the consolidated financial statements for all
periods thereafter up to the Closing reflect or will reflect, as the case may
be, all liabilities (whether accrued, absolute, contingent, unliquidated or
otherwise, whether due or to become due and regardless of when asserted) as of
such date of it and its Subsidiaries required to be reflected in such financial
statements in accordance with generally accepted accounting principles and
contain or will contain (as the case may be) adequate reserves for losses on
loans and properties acquired in settlement of loans, taxes and all other
material accrued liabilities and for all reasonably anticipated material losses,
if any, as of such date in accordance with generally accepted accounting
principles. There exists no set of circumstances that could reasonably be
expected to result in any liability or obligation material to it or its
Subsidiaries, taken as a whole, except as disclosed in such consolidated
financial statements at December 31, 1999 or for transactions effected or
actions occurring or omitted to be taken after December 31, 1999 (i) in the
ordinary course of business, (ii) as permitted by this Agreement, or (iii) as
disclosed in its Regulatory Reports filed after December 31, 1999 and before the
date of this Agreement. A true and complete copy of such December 31, 1999
financial statements has been delivered by it to the other parties.
II To the extent permitted under applicable law, it has delivered or
made available to the other parties each Regulatory Report filed, used or
circulated by it with respect to periods since February 1, 1996 through the date
of this Agreement and will promptly deliver to the other parties each such
Regulatory Report filed, used or circulated after the date hereof, each in the
form (including exhibits and any amendments thereto) filed with the applicable
regulatory or governmental entity (or, if not so filed, in the form used or
circulated).
V Absence of Changes. With respect to Ampersand and AccuMed:
I Since the date on which a Report on Form 10-Q was most recently
filed by or on its behalf with the SEC, there has been no material adverse
change affecting it. There is no occurrence, event or development of any nature
existing or, to its best knowledge, threatened which may reasonably be expected
to have a material adverse effect upon it.
II Except as set forth in Section 2.5 of its Disclosure Schedules or
in its Regulatory Reports filed after December 31, 1999 and before the date of
this Agreement, since December 31, 1999, each of it and its Subsidiaries has
owned and operated its respective assets, properties and businesses in the
ordinary course and consistent with past practice.
VI Prospectus/Proxy Statement. At the time the Prospectus/Proxy Statement
is mailed to the AccuMed stockholders for the solicitation of proxies for the
approval referred to in
14
19
Section 1.7(a) hereof and at all times after such mailings up to and including
the time of such approval, such Prospectus/Proxy Statement (including any
supplements thereto), with respect to all information set forth therein relating
to it (including its Subsidiaries) and its stockholders, its securities, this
Agreement, the Merger and the other transactions contemplated hereby, will:
I Comply in all material respects with applicable provisions of
the Securities Act, the Exchange Act and the rules and regulations under such
Acts; and
II With respect to itself, and with respect to any information
supplied by it, not contain any untrue statement of a material fact or omit to
state any material fact required to be stated therein or necessary in order to
make the statements contained therein, in light of the circumstances under which
it is made, not misleading.
VII No Broker's or Finder's Fees. No agent, broker, investment banker,
person or firm acting on behalf or under authority of it or any of its
Subsidiaries is or will be entitled to any broker's or finder's fee or any other
commission or similar fee directly or indirectly in connection with the Merger
or any other transaction contemplated hereby, except as set forth in Section 2.7
of its Disclosure Schedules.
VIII Litigation and Other Proceedings. Except for matters which would
not have a material adverse effect on it, or except as set forth in Section 2.8
of its Disclosure Schedules, neither it nor any of its Subsidiaries is a
defendant in, nor is any of its property subject to, any pending or, to its best
knowledge, threatened claim, action, suit, investigation or proceeding or
subject to any judicial order, judgment or decree.
IX Compliance with Law. Except as set forth in Section 2.9 of its
Disclosure Schedules:
I It and each of its Subsidiaries are in compliance in all material
respects with all laws, regulations, ordinances, rules, judgments, orders and
decrees applicable to their respective operations and businesses, and neither it
nor any of its Subsidiaries has received notice from any federal, state or local
government or governmental agency of any material violation of, and does not
know of any material violations of, any of the above;
II It and each of its Subsidiaries has all permits, licenses,
certificates of authority, orders and approvals of, and have made all filings,
applications and registrations with, all federal, state, local and foreign
governmental or regulatory bodies that are required in order to permit them to
carry on their respective businesses as they are presently being conducted;
III Other than with respect to those matters that have been cured or
corrected, neither it nor any of its Subsidiaries has received since February 1,
1996 any notification or
15
20
communication from any governmental or regulatory entity or the staff thereof
(A) asserting that it or any of its Subsidiaries is not in material compliance
with any of the statutes, regulations or ordinances that such governmental or
regulatory entity administers or enforces; (B) threatening to revoke any
material license, franchise, permit or authorization; or (C) threatening or
contemplating any enforcement action by or supervisory or other written
agreement with a state or federal regulator (nor, to the knowledge of its
executive officers, do any grounds for any of the foregoing exist); and
IV Neither it nor any of its Subsidiaries is required to give prior
notice to any regulatory agency of the proposed addition of an individual to
their respective Board of Directors or the employment of an individual as a
senior executive officer.
X Corporate Actions.
I Its Board of Directors has (i) duly approved the Merger and this
Agreement, and authorized its officers to execute and deliver this Agreement,
and to take all action necessary to consummate the Merger and the other
transactions contemplated hereby, and (ii) authorized and directed the
submission for approval or adoption of this Agreement by all persons whose
consent or approval may be necessary or required in regard thereto.
II Its Board of Directors has taken all necessary action to exempt
this Agreement and the transactions contemplated hereby from, and this Agreement
and the transactions contemplated hereby are exempt from, (i) any applicable
state takeover laws, (ii) any state laws limiting or restricting the voting
rights of stockholders, (iii) any state laws requiring a stockholder approval
vote in excess of the vote normally required in transactions of a similar type
not involving a "related person," "interested stockholder" or person or entity
of a similar type, and (iv) any provision in its or any of its Subsidiaries'
articles of incorporation, certificate of incorporation, charter or bylaws, (A)
restricting or limiting stock ownership or the voting rights of stockholders
(other than the provisions of AccuMed's Certificate of Incorporation that limit
the voting rights of the holders of the AccuMed Preferred Stock), or (B)
requiring a stockholder approval vote in excess of the vote normally required in
transactions of a similar type not involving a "related person," interested
stockholder" or person or entity of a similar type.
XI Authority. Except as set forth in Section 2.11 of its Disclosure
Schedules, neither the execution nor delivery of, nor performance of any
obligations under, this Agreement by it, nor the consummation of the Merger,
will violate any of the provisions of, or constitute a breach or default under,
or give any person the right to terminate or accelerate payment or performance
under, (i) its articles of incorporation, certificate of incorporation or
bylaws, or the articles of incorporation, certificate of incorporation, charter
or bylaws of any of its Subsidiaries, (ii) any regulatory restraint on the
acquisition of it or control thereof, (iii) any law, rule, ordinance, regulation
or judgment, decree, order, award or governmental or non-governmental permit or
16
21
license to which it or any of its Subsidiaries is subject, or (iv) any
agreement, lease, contract, note, mortgage, indenture, arrangement or other
obligation or instrument ("Contract") to which it or any of its Subsidiaries is
a party or is subject or by which any of its or their properties or assets is
bound and which provides for payments by, on behalf of, or to it and/or any of
its Subsidiaries in excess of either $25,000 per annum or $100,000 over the term
of such Contract. The parties acknowledge that the consummation of the Merger
and the other transactions contemplated hereby is subject to various regulatory
approvals. It has all requisite corporate power and authority to enter into this
Agreement and to perform its obligations hereunder and thereunder, subject in
the case of the Merger to the approval or adoption of this Agreement by its
stockholders under applicable law. Other than (i) the receipt of Governmental
Approvals (as defined in Section 4.1(c)), (ii) the approval or adoption of this
Agreement by its stockholders, and (iii) except as set forth in Section 2.11 of
its Disclosure Schedules with respect to any Contract, no consents or approvals
are required on its behalf or on behalf of any of its Subsidiaries in connection
with the consummation of the transactions contemplated by this Agreement. This
Agreement constitutes the valid and binding obligations of it, enforceable in
accordance with their terms, except as enforceability may be limited by
applicable laws relating to bankruptcy, insolvency or creditors' rights
generally and general principles of equity.
XII Employment Arrangements. Except as set forth in Section 2.12 of its
Disclosure Schedules, there are no agreements, plans or other arrangements with
respect to employment, severance or other benefits with any current or former
directors, officers or employees of it or any of its Subsidiaries which may not
be terminated without penalty or expense (including any augmentation or
acceleration of benefits) on thirty (30) days' or less notice to any such
person. Except as set forth in Section 2.12 of its Disclosure Schedules, no
payments or benefits (including any augmentation or acceleration thereof) to
current or former directors, officers or employees of it or any of its
Subsidiaries resulting from the transactions contemplated hereby or the
termination of such person's service or employment within two (2) years after
completion of the Merger will cause the imposition of excise taxes under Section
4999 of the Internal Revenue Code or the disallowance of a deduction to it, the
Surviving Corporation, or any of their respective Subsidiaries pursuant to
Sections 162 or 280G, or any other section of the Internal Revenue Code.
XIII Employee Benefits.
17
22
I Neither it nor any of its Subsidiaries maintains any funded
deferred compensation plans (including profit sharing, pension, retirement
savings or stock bonus plans), unfunded deferred compensation arrangements or
employee benefit plans as defined in Section 3(3) of the Employee Retirement
Income Security Act of 1974, as amended ("ERISA"), other than any plans
("Employee Plans") set forth in Section 2.13 of its Disclosure Schedules (true
and correct copies of which it has delivered to the other parties). Neither it
nor any of its Subsidiaries has incurred or reasonably expects to incur any
liability to the Pension Benefit Guaranty Corporation, except for required
premium payments which, to the extent due and payable, have been paid. The
Employee Plans intended to be qualified under Section 401(a) of the Internal
Revenue Code are so qualified, and it is not aware of any fact which would
adversely affect the qualified status of such plans. Except as set forth in
Section 2.13 of its Disclosure Schedules, neither it nor any of its Subsidiaries
(a) provides health, medical, death or survivor benefits to any former employee
or beneficiary thereof, or (b) maintains any form of current (exclusive of base
salary and base wages) or deferred compensation, bonus, stock option, stock
appreciation right, benefit, severance pay, retirement, employee stock
ownership, incentive, group or individual health insurance, welfare or similar
plan or arrangement for the benefit of any single or class of directors,
officers or employees, whether active or retired (collectively "Benefit
Arrangements").
II Except as disclosed in Section 2.13 of its Disclosure Schedules,
all Employee Plans and Benefit Arrangements that are currently in effect were in
effect for substantially all of calendar year 1999 and there has been no
material amendment thereof (other than amendments required to comply with
applicable law) or increase in the cost thereof or benefits payable thereunder
on or after February 1, 1999.
III To its best knowledge, with respect to all Employee Plans and
Benefit Arrangements, it and each of its Subsidiaries are in substantial
compliance with the requirements prescribed by any and all statutes,
governmental or court orders or rules or regulations currently in effect,
including but not limited to ERISA and the Internal Revenue Code, applicable to
such Employee Plans or Benefit Arrangements. To its best knowledge, no condition
exists that could constitute grounds for the termination of any Employee Plan
under Section 4042 of ERISA; no "prohibited transaction," as defined in Section
406 of ERISA and Section 4975 of the Internal Revenue Code, has occurred with
respect to any Employee Plan, or any other employee benefit plan maintained by
it or any of its Subsidiaries which is covered by Title I of ERISA, which could
subject any person to liability under Title I of ERISA or to the imposition of
any tax under Section 4975 of the Internal Revenue Code; to its best knowledge,
no Employee Plan subject to Part III of Subtitle B of Title I of ERISA or
Section 412 of the Internal Revenue Code, or both, has incurred any "accumulated
funding deficiency," as defined in Section 412 of the Internal Revenue Code,
whether or not waived; neither it nor any of its Subsidiaries has failed to make
any contribution or pay any amount due and owing as required by the terms of any
Employee Plan or Benefit Arrangement. To its best knowledge, neither it nor any
of its Subsidiaries has incurred or expects to incur, directly or indirectly,
any liability under Title IV of ERISA arising in connection with the
18
23
termination of, or a complete or partial withdrawal from, any plan covered or
previously covered by Title IV of ERISA which could constitute a liability of
the Surviving Corporation or any of its Subsidiaries at or after the Merger
Effective Time.
XIV Information Furnished. No statement contained in any schedule,
certificate or other document furnished (whether before, on or after the
Execution Date) or to be furnished in writing by or on behalf of it to the other
parties pursuant to this Agreement contains or will contain any untrue statement
of a material fact or any material omission. To its best knowledge, no
information that is material to the Merger and necessary to make the
representations and warranties herein not misleading has been withheld from the
other parties hereto.
XV Property and Assets. It and its Subsidiaries have good and marketable
title to all of their real property reflected in their financial statements at
December 31, 1999, referred to in Section 2.4 hereof or acquired subsequent
thereto, free and clear of all Encumbrances, except for (a) such items shown in
such financial statements or in the notes thereto, (b) liens for current real
estate taxes not yet delinquent, (c) customary easements, restrictions of record
and title exceptions that are not material to the value or use of such property,
(d) property sold or transferred in the ordinary course of business since the
date of such financial statements, (e) as otherwise specifically indicated in
its Regulatory Reports filed after December 31, 1999 and before the Execution
Date or in Section 2.15 of its Disclosure Schedules. It and its Subsidiaries
enjoy peaceful and undisturbed possession under all material leases for the use
of real property under which they are the lessee; all of such leases are valid
and binding and in full force and effect, and neither it nor any of its
Subsidiaries is in default in any material respect under any such lease. No
default will arise under any material real property, material personal property
lease or material intellectual property license by reason of the consummation of
the Merger without the lessor's or licensor's consent except as set forth in
Section 2.15 of its Disclosure Schedules. There has been no material physical
loss, damage or destruction, whether or not covered by insurance, affecting any
of the real property or material personal property of it or its Subsidiaries
since December 31, 1999. All fixed assets material to its or any of its
Subsidiaries) respective businesses and currently used by it or any of its
Subsidiaries are, in all material respects, in good operating condition and
repair.
XVI Agreements and Instruments. Except as set forth in its Regulatory
Reports filed after December 31, 1999 and before the Execution Date or in
Section 2.16 of its Disclosure Schedules, neither it nor any of its Subsidiaries
is a party to (a) any material agreement, arrangement or commitment not made in
the ordinary course of business, (b) any agreement, indenture or other
instrument relating to the borrowing of money by it or any of its Subsidiaries
or the guarantee by it or of its Subsidiaries of any such obligation, (c) any
agreements to make loans or for the provision, purchase or sale of goods,
services or property between it or any of its Subsidiaries and any director or
officer of it or any of its Subsidiaries or any affiliate or member of the
immediate family of any of the foregoing, (d) any agreements with or concerning
any labor
19
24
or employee organization to which it or any of its Subsidiaries is a party, (e)
any agreements between it or any of its Subsidiaries and any five percent (5%)
or more stockholder of it, and (f) any agreements, directives, orders or similar
arrangements between or involving it or any of its Subsidiaries and any state or
regulatory authority.
XVII Material Contract Default; Contingent Liabilities. Neither it nor any
of its Subsidiaries, nor any counterparty thereto, is in default in any respect
under any contract, agreement, commitment, arrangement, lease, insurance policy
or other instrument to which it or any Subsidiary of it is a party or by which
its respective assets, business or operations may be bound or affected or under
which it or its respective assets, business or operations receives benefits,
which default is reasonably expected to have, either individually or in the
aggregate, a material adverse effect on it, and, except as set forth in Section
2.17 of its Disclosure Schedules, there has not occurred any event that, with
the lapse of time or the giving of notice or both, would constitute such a
default, and neither it nor any of its Subsidiaries has been given notice or is
aware of any material, actual or contingent liability of any kind or nature that
has not been disclosed to the other party hereunder, whether or not such type of
liability is specifically mentioned in any provision of this Agreement.
Furthermore, without limiting the generality of the foregoing, each party and
its Subsidiaries has received all payments due to it under any and all existing
contracts or other business arrangements in a timely fashion as of the Execution
Date, and no payments under any such contracts or arrangements are, or are
reasonably expected to become, in arrears from and after the date hereof and
through and including the Merger Effective Time.
XVIII Tax Matters.
I It and each of its Subsidiaries has duly and properly filed all
federal, state, local and other tax returns and reports required to be filed by
it or them and has made timely payments of all taxes due and payable, whether
disputed or not; the current status of audits of such returns or reports by the
Internal Revenue Service and other applicable tax authorities is as set forth in
Section 2.18 of its Disclosure Schedules; and, except as set forth in Section
2.18 of its Disclosure Schedules, there is no agreement by it or any of its
Subsidiaries for the extension of time for the assessment or payment of any
taxes payable. Except as set forth in Section 2.18 of its Disclosure Schedules,
neither the Internal Revenue Service nor any other taxing authority is now
asserting or, to its best knowledge, threatening to assert any deficiency or
claim for additional taxes (or interest thereon or penalties in connection
therewith), nor is it aware of any basis for any such assertion or claim,
including, but not limited to, any notification from its independent auditors,
whether formal or informal, that any position taken by it or its Subsidiaries on
any return or information report is inconsistent with established precedent and
more likely than not to be challenged upon audit by the relevant taxing
authority. It and each of its Subsidiaries has complied in all material respects
with all applicable Internal Revenue Service backup withholding requirements. It
and each of its Subsidiaries has complied with all applicable state law tax
collection and reporting requirements.
20
25
II Adequate provision for any unpaid federal, state, local or
foreign taxes due or to become due from it or any of its Subsidiaries for all
periods through and including September 30, 2000 has been made and is reflected
in its September 30, 2000 financial statements referred to in Section 2.4, and
has been or will be made with respect to periods ending after September 30,
2000.
XIX Environmental Matters. To its best knowledge, neither it nor any of
its Subsidiaries owns, leases, or otherwise controls any property affected by
toxic waste, radon gas or other hazardous conditions or constructed in part with
the use of asbestos which requires removal or encapsulation. Neither it nor any
of its Subsidiaries is aware of, nor has it or any of its Subsidiaries received
written notice from any governmental or regulatory body of, any past, present or
future conditions, activities, practices or incidents which may interfere with
or prevent compliance or continued compliance with hazardous substance or other
environmental laws or any regulation, order, decree, judgment or injunction,
issued, entered, promulgated or approved thereunder or which may give rise to
any common law or legal liability or otherwise form the basis of any claim,
action, suit, proceeding, hearing or investigation based on or related to the
manufacture, processing, distribution, use, treatment, storage, disposal,
transport or handling, or the emission, discharge, release or threatened release
into the environment, of any pollutant, contaminant, chemical or industrial,
toxic or hazardous substance or waste. There is no civil, criminal or
administrative claim, action, suit, proceeding, hearing or investigation pending
or, to its knowledge, threatened against it or any of its Subsidiaries relating
in any way to such hazardous substance laws or any regulation, order, decree,
judgment or injunction issued, entered, promulgated or approved thereunder.
XX Exceptions to Representations and Warranties.
I On or before the date hereof, AccuMed has delivered to Ampersand
and Acquisition Sub, and Ampersand and Acquisition Sub have delivered to
AccuMed, their respective Disclosure Schedules, setting forth, among other
things, exceptions to any and all of their respective representations and
warranties contained in this Article II, provided that each exception set forth
in a Disclosure Schedule shall be deemed disclosed for purposes of all
representations and warranties if such exception is contained in a section of a
Disclosure Schedule corresponding to a Section in Article II, and provided
further that (i) no such exception is required to be set forth in a Disclosure
Schedule if its absence would not result in the related representation or
warranty being deemed untrue or incorrect under the standard established by
Section 2.20(b) hereof, and (ii) the mere inclusion of an exception in a
Disclosure Schedule shall not be deemed an admission by a party that such
exception represents a material fact, event or circumstance or would result in a
material adverse effect or material adverse change.
II None of the representations or warranties of the parties hereto
contained in this Article II shall be deemed untrue or incorrect, and no party
shall be deemed to have breached
21
26
its representations or warranties contained herein, as a consequence of the
existence of any fact, circumstance or event if such fact, circumstance or
event, individually or taken together with all other facts, circumstances or
events, would not have a material adverse effect or material adverse change on
such party. As used in this Agreement, the term "material adverse effect" or
"material adverse change" means an effect or change which (i) is materially
adverse to the financial condition of a party and its respective Subsidiaries
taken as a whole, (ii) significantly and adversely affects the ability of
AccuMed, Ampersand or Acquisition Sub to consummate the transactions
contemplated hereby or to perform its material obligations hereunder, or (iii)
enables any person to prevent the consummation of the transactions contemplated
hereby; provided, however, that any effect or change resulting from (A) actions
or omissions of the parties hereto contemplated by this Agreement or taken with
the prior consent of the other parties in contemplation of the transactions
provided for herein (including, without limitation, conforming accounting
adjustments), or (B) circumstances generally affecting the industry or
industries within which the parties operate (including changes in laws or
regulations, accounting principles or general levels of interest rates) which do
not adversely affect a party and its Subsidiaries, taken as a whole, in a manner
significantly different than the other parties hereto, shall be deemed not to be
or have a material adverse effect or result in a material adverse change.
ARTICLE III
COVENANTS
I Investigations; Access and Copies. From and after the date of this
Agreement, and through and including the Merger Effective Time, each party
agrees to give to the other parties and their respective representatives and
agents full access (to the extent lawful) to all of the premises, books, records
and employees of it and its Subsidiaries at all reasonable times and to furnish
and cause its Subsidiaries to furnish to the other party and its respective
agents or representatives access to and true and complete copies of such
financial and operating data, all documents with respect to matters to which
reference is made in Article II hereof or on any list, schedule or certificate
delivered or to be delivered in connection herewith and such other documents,
records or information with respect to the businesses and properties of it and
its Subsidiaries as the other party or its respective agents or representatives
shall from time to time reasonably request; provided however, that any such
inspection (a) shall be conducted in such manner as not to interfere
unreasonably with the operation of the business of the entity inspected, and (b)
shall not affect any of the representations or warranties hereunder. Each party
will also give prompt written notice to the other parties of any event or
development which, (x) had it existed or been known on the date of this
Agreement, would have been required to be disclosed under this Agreement, (y)
would cause any of its representations and warranties contained herein to be
inaccurate or otherwise materially misleading, or (z) materially relates to the
satisfaction of the conditions set forth in Article IV hereof. Notwithstanding
anything to the contrary contained herein, none of the parties hereto nor any of
their respective Subsidiaries shall be required to provide access to or to
disclose information where such access or disclosure would jeopardize the
22
27
attorney-client privilege of the entity in possession or control of such
information or contravene any law, rule, regulation, order, judgment, decree,
fiduciary duty or binding agreement entered into prior to the date of this
Agreement or, in the event of any litigation or threatened litigation among the
parties over the terms of this Agreement, where access to information may be
adverse to the interests of such party. To the extent reasonably practicable,
the parties hereto will make appropriate substitute disclosure arrangements
under circumstances in which the restrictions of the preceding sentence apply.
II Conduct of Business. From and after the date of this Agreement, and
through and including the Merger Effective Time or the termination of this
Agreement, each party agrees, on behalf of itself and each of its respective
Subsidiaries, except insofar as the Chief Executive Officer of each of the
parties shall otherwise consent in writing (which consent shall not be
unreasonably withheld):
I That it and its Subsidiaries shall (i) except as contemplated in
this Agreement conduct their business only in the ordinary course consistent
with past practices, (ii) maintain their books and records in accordance with
past practices, and (iii) use all reasonable efforts to preserve intact their
business organizations and assets, to maintain their rights, franchises and
existing relations with customers, suppliers, employees and business associates
and to take no action that would (A) adversely affect the ability of any of them
to obtain the Governmental Approvals (as defined in Section 4.1(c) hereof) or
which would reasonably be expected to hinder or delay receipt of the
Governmental Approvals, or (B) adversely affect their ability to perform their
obligations under this Agreement;
II That, except as specifically otherwise permitted herein, neither
it nor its Subsidiaries shall: (i) declare, set aside or pay any dividend or
make any other distribution with respect to its capital stock, except for
dividends or distributions by a wholly-owned Subsidiary of such party to such
party; (ii) reacquire or buy any of its outstanding shares; (iii) issue or sell
any shares of capital stock of it or any of its Subsidiaries, except shares of
its common stock issued pursuant to exercise or conversion of stock options,
warrants, convertible preferred stock or convertible notes outstanding on the
Execution Date, if any, and which have been identified in its Disclosure
Schedules; (iv) effect any stock split, stock dividend, reverse stock split or
other reclassification or recapitalization of its common stock; or (v) grant any
stock appreciation or other rights with respect to shares of capital stock of it
or of any of its Subsidiaries; or (vi) enter into any agreement, or make any
modification to any authorized or issued security, the effect of which is to
cause the exercise price of any security convertible into shares of Ampersand
Common Stock to be reduced upon consummation of the Merger or the transactions
contemplated hereby;
III That, except as specifically otherwise permitted herein, neither
it nor its Subsidiaries shall: (i) sell, dispose of or pledge any significant
assets of it or of any of its Subsidiaries other than in the ordinary course of
business consistent with past practices or to
23
28
borrow funds consistent with the provisions hereinafter contained except as
contemplated in Schedule 3.2 of its Disclosure Schedules; (ii) merge or
consolidate it or any of its Subsidiaries into another entity or acquire any
other entity or, except in accordance with its written business plan in effect
on the date hereof, acquire any significant assets; (iii) sell or pledge or
agree to sell or pledge or permit any lien to exist on any stock of any of its
Subsidiaries owned by it; (iv) change the articles of incorporation or
certificate of incorporation, charter, bylaws or other governing instruments of
it or any of its Subsidiaries, except, in the case of Ampersand, with respect to
the authorization of additional shares of Ampersand Common Stock, or otherwise
as contemplated by this Agreement; (v) engage in any lending activities other
than in the ordinary course of business consistent with past practices; (vi)
form any new subsidiary or cause or permit a material change in the activities
presently conducted by any Subsidiary or make additional investments in
subsidiaries in excess of $100,000, except as contemplated in Schedule 3.2 of
its Disclosure Schedules; (vii) engage in any off balance sheet interest rate
swap arrangement, (viii) engage in any activity not contemplated by its written
business plan in effect on the Execution Date; (ix) purchase any equity
securities or incur or assume any indebtedness except in the ordinary and usual
course of business; (x) authorize capital expenditures other than in the
ordinary and usual course of business; or (xi) implement or adopt any change in
its accounting principles, practices or methods other than as may be required by
generally accepted accounting principles (the limitations contained in this
Section 3.2 (c) shall also be deemed to constitute limitations as to the making
of any commitment with respect to any of the matters set forth in this Section
3.2 (c)); and
IV That, except (i) for the Seventy-Five Thousand Dollar ($75,000)
aggregate bonus allocation to officers, directors and key employees heretofore
approved by the Board of Directors of AccuMed for the fiscal year ending on
December 31, 2000, (ii) the severance agreement heretofore entered into by
AccuMed with Xxxxxx Xxxxxxxx, and (iii) as specifically otherwise permitted
herein, neither it nor its Subsidiaries shall: (w) grant any general increase in
compensation or benefits to its employees or officers or pay any bonuses to its
employees or officers except in accordance with policies in effect on the
Execution Date; (x) enter into, extend, renew, modify, amend or otherwise change
any employment or severance agreements with any of its directors, officers or
employees; (y) grant any increase in fees or other increases in compensation or
other benefits to any of its present or former directors in such capacity; or
(z) establish or sponsor any new Employee Plan or Benefit Arrangement or effect
any change in its Employee Plans or Benefit Arrangements.
III No Solicitation. Each party agrees, on behalf of itself and each of
its Subsidiaries, that, from and after the date hereof, it will not authorize or
permit any officer, director, employee, investment banker, financial consultant,
attorney, accountant or other representative of it or any of its Subsidiaries,
directly or indirectly, to initiate contact with any person or entity in an
effort to solicit, initiate or encourage any Takeover Proposal (as such term is
defined below). Except as the fiduciary duties of its Board of Directors may
otherwise require (as determined in good faith after consultation with legal
counsel), each party agrees that it will not authorize or permit any officer,
director, employee, investment banker, financial consultant,
24
29
attorney, accountant or other representative of it or any of its Subsidiaries,
directly or indirectly, (i) to cooperate with, or furnish or cause to be
furnished any non-public information concerning its business, properties or
assets to, any person or entity in connection with any Takeover Proposal; (ii)
to negotiate any Takeover Proposal with any person or entity; or (iii) to enter
into any agreement, letter of intent or agreement in principle as to any
Takeover Proposal. Each party agrees that it shall promptly give written notice
to the other upon becoming aware of any Takeover Proposal, such notice to
contain, at a minimum, the identity of the persons submitting the Takeover
Proposal, a copy of any written inquiry or other communication, the terms of any
Takeover Proposal, any information requested or discussions sought to be
initiated and the status of any requests, negotiations or expressions of
interest. As used in this Agreement, "Takeover Proposal" shall mean any
proposal, other than as contemplated by this Agreement, for a merger or other
business combination involving any of the parties hereto or any of their
respective Subsidiaries, or for the acquisition of an equity interest in any of
the parties hereto that would give rise to a filing requirement with the SEC (as
mandated by federal securities law), or for the acquisition of an equity
interest greater than five percent (5%) in any of their respective Subsidiaries,
or for the acquisition of a substantial portion of the assets of any party
hereto or any of their respective Subsidiaries.
IV Stockholder Approvals. AccuMed shall call the AccuMed Stockholders'
Meeting, and Ampersand, as the sole shareholder of Acquisition Sub, shall, by
informal action, approve this Agreement and the transactions contemplated
hereby, in accordance with the provisions of Section 1.7 hereof. In connection
with the AccuMed Stockholders' Meeting, the Board of Directors of AccuMed shall
recommend approval of this Agreement and, the transactions contemplated hereby
(and such recommendation shall be contained in the Prospectus/Proxy Statement),
unless as a result of an unsolicited Takeover Proposal received by a party after
the date hereof the Board of Directors of AccuMed determines in good faith,
after consultation with its legal counsel, that to approve or to recommend
approval by the stockholders of this Agreement and the transactions contemplated
hereby would constitute a breach of the fiduciary duties of such Board of
Directors to the stockholders of AccuMed. AccuMed shall use its best efforts to
solicit from its stockholders proxies in favor of approval and to take all other
action necessary or helpful to secure a vote of the AccuMed stockholders in
favor of this Agreement and the transactions contemplated hereby, except as the
fiduciary duties of its Board of Directors may otherwise require.
V Accounting and Tax Treatment. After execution of this Agreement, none
of the parties hereto shall take any action which would prevent the Merger and
the other transactions contemplated hereby from qualifying as a reorganization
within the meaning of Section 368 of the Internal Revenue Code.
VI Publicity. From and after the Execution Date, and through and
including the Merger Effective Time, none of the parties hereto nor any of their
respective Subsidiaries shall, without the prior approval of the other parties
hereto, issue or make, or permit any of its directors,
25
30
employees, officers or agents to issue or make, any press release, disclosure or
statement to the press or any third party with respect to the Merger or the
other transactions contemplated hereby, except as required by law. The parties
hereto shall cooperate when issuing or making any press release, disclosure or
statement with respect to the Merger or the other transactions contemplated
hereby.
VII Cooperation Generally. From and after the Execution Date, and
through and including the Merger Effective Time, the parties hereto and their
respective Subsidiaries shall, in conformance with the provisions of this
Agreement, use their best efforts, and take all actions necessary or
appropriate, to consummate the Merger and the other transactions contemplated
hereby at the earliest practicable date.
VIII Additional Financial Statements and Reports. As soon as reasonably
practicable after they become publicly available, Ampersand and AccuMed shall
furnish to each other their respective statements of financial condition,
statements of operations or statements of income, statements of cash flows and
statements of changes in stockholders' equity at all dates and for all periods
before the Closing. Such financial statements will be prepared in conformity
with generally accepted accounting principles applied on a consistent basis and
fairly present the financial condition, results of operations and cash flows of
the respective parties (subject, in the case of unaudited financial statements,
to (i) normal year-end audit adjustments, (ii) any other adjustments described
therein, and (iii) the absence of notes which, if presented, would not differ
materially from those included with its most recent audited consolidated
financial statements), and all of such financial statements will be prepared in
conformity with the requirements of Form 10-Q or Form 10-K, as and if
applicable, under the Exchange Act. As soon as reasonably practicable after they
are filed, each of Ampersand and AccuMed shall, to the extent permitted under
applicable law, furnish to the other its own Regulatory Reports.
IX Employee Benefits and Agreements.
I Following the Merger Effective Time, Ampersand or the Surviving
Corporation shall honor, in accordance with their respective terms, all Benefit
Arrangements and all provisions for vested benefits or other vested amounts
theretofore earned or accrued under the Employee Plans of each of the parties
hereto.
II The aforesaid Employee Plans shall not be terminated by reason
of the Merger but shall continue thereafter as plans of Ampersand or the
Surviving Corporation until such time as the Employee Plans are integrated,
subject to the terms and conditions specified in such plans and to such changes
therein as may be necessary to reflect the consummation of the Merger. Ampersand
or the Surviving Corporation shall take such steps as are necessary as soon as
practicable following the Merger Effective Time to integrate the Employee Plans,
with (i) full credit for prior service with AccuMed or Ampersand or any of the
AccuMed or Ampersand
26
31
Subsidiaries for purposes of vesting and eligibility for participation (but not
benefit accruals under any Employee Plan) and co-payments and deductibles, and
(ii) waiver of all waiting periods and pre-existing condition exclusions or
penalties.
X Ampersand Lock-Up Agreements. Ampersand shall cause each officer and
director of Ampersand, and Acquisition Sub shall cause each officer and director
of Acquisition Sub, to furnish to AccuMed, on or prior to the Closing Date, a
letter, in form and substance satisfactory to counsel for AccuMed, pursuant to
which each such person shall agree not to offer for sale, sell, distribute or
otherwise dispose of any shares of Ampersand Common Stock during the sixty (60)
days following the Closing Date.
ARTICLE IV
CONDITIONS OF THE MERGER; TERMINATION OF AGREEMENT
I Conditions to the Obligations of Each Party. The obligations of each
party to effect the Merger shall be subject to the satisfaction (or written
waiver by such party, to the extent such condition is waivable) of the following
conditions before the Merger Effective Time:
I Stockholder Approval. The respective stockholders of AccuMed and
Acquisition Sub shall have approved or adopted this Agreement as specified in
Section 1.7 hereof or as otherwise required by applicable law.
II No Proceedings. No order shall have been entered and remain in
force restraining or prohibiting the Merger in any legal, administrative,
arbitration, investigatory or other proceedings by any governmental or judicial
or other authority.
III Governmental Approvals. To the extent required by applicable law
or regulation, all approvals of or filings with any governmental or regulatory
authority (collectively, "Governmental Approvals") shall have been obtained or
made, and any waiting periods shall have expired in connection with the
consummation of the Merger; provided, however, that none of the preceding shall
be deemed obtained or made if it shall be conditioned or restricted in a manner
that would have or result in a material adverse effect on the Surviving
Corporation as the parties hereto shall reasonably and in good faith agree. All
other statutory or regulatory requirements for the valid consummation of the
Merger shall have been satisfied.
IV Registration Statement. The Registration Statement shall have
been declared effective and shall not be subject to a stop order of the SEC (and
no proceedings for that purpose shall have been initiated or threatened by the
SEC) and, if the offer and sale of the Ampersand Common Stock in the Merger
pursuant to this Agreement is subject to the securities laws of any state, shall
not be subject to a stop order of any state securities authority.
27
32
V Legal Opinions. AccuMed shall have received the opinion letter
of Schwartz, Cooper, Xxxxxxxxxxx & Xxxxxx, Chartered, counsel to Ampersand and
Acquisition Sub, and Ampersand and Acquisition Sub shall have received the
opinion letter of Xxxxx X. Xxxxxxx, Esq., counsel to AccuMed, in each case in
form and substance satisfactory to the party or parties to whom addressed and to
counsel for such party or parties, with respect to those matters customarily the
subject of such opinion letters in transactions of the nature and magnitude of
the transactions contemplated by this Agreement.
VI Federal Tax Opinion. Ampersand and Acquisition Sub shall have
received an opinion of tax counsel, dated as of the Closing Date, to the effect
that for federal income tax purposes:
I The Merger will qualify as a "reorganization" under Section
368(a) of the Internal Revenue Code;
II No gain or loss will be recognized by any party hereto by
reason of the Merger;
III The basis of the Ampersand Common Stock received by each
holder of AccuMed Common Stock who exchanges AccuMed Common Stock for
Ampersand Common Stock, and the basis of the Ampersand Preferred Stock
received by each holder of AccuMed Preferred Stock who exchanges AccuMed
Preferred Stock for Ampersand Preferred Stock, in the Merger will be the
same as the basis of the AccuMed security surrendered in exchange therefor
(subject, in the case of the AccuMed Common Stock, to any adjustments
required as the result of receipt of cash in lieu of a fractional share of
Ampersand Common Stock);
IV The holding period of the Ampersand Common Stock received
by a holder of AccuMed Common Stock, and the holding period of the
Ampersand Preferred Stock received by a holder of AccuMed Preferred Stock,
in the Merger will include the holding period of the AccuMed Common Stock
surrendered in exchange therefor, provided that such shares of AccuMed
Common Stock or AccuMed Preferred Stock, as the case may be, were held as a
capital asset by such stockholder at the Merger Effective Time; and
V Cash received by an AccuMed stockholder in lieu of a
fractional share interest of Ampersand Common Stock as part of the Merger
will be treated as having been received as a distribution in full payment
in exchange for the fractional share interest of Ampersand Common Stock
which such stockholder would otherwise be entitled to receive and will
qualify as capital gain or loss (assuming the AccuMed Common Stock was a
capital asset in such stockholder's hands at the Merger Effective Time).
28
33
VII Third Party Consents. All consents or approvals of all persons
required for the execution, delivery and performance of this Agreement and the
consummation of the Merger, including, but not limited to, the consents or
approvals of all counterparties to existing material business contracts that
contain provisions requiring that such consent or approval be given, and the
Governmental Approvals referenced in Section 4.1(c) hereof shall have been
obtained and shall be in full force and effect, unless the failure to obtain any
such consent or approval is not reasonably likely to have, individually or in
the aggregate, a material adverse effect on the Surviving Corporation as the
parties shall reasonably and in good faith agree.
VIII Material Business Contracts. In its Disclosure Schedules, each
party hereto shall have delivered to the others a list of all material business
contracts to which the listing party is a party or by which it is bound or from
which it benefits, which list shall be true and complete as of the Closing.
IX Due Diligence Reviews.
(i) During the period from the Execution Date through the
Closing Date, Ampersand and Acquisition Sub shall be given the opportunity
by AccuMed, at all reasonable times during normal business hours, to
conduct a due diligence review of AccuMed and its business operations,
which shall include but not be limited to, a review of all books and
records and the opportunity to talk to such employees and contract
counterparties as the parties shall reasonably agree upon, and, at the same
time, AccuMed will be given the opportunity by Ampersand and Acquisition
Sub to conduct a similar due diligence review of Ampersand and Acquisition
Sub and their respective business operations.
(ii) In the event that Ampersand or Acquisition Sub, on the one
hand, or AccuMed, on the other hand, should identify during the course of
the due diligence review being conducted by it hereunder, any matter or
matters that, alone or in the aggregate, may have a material adverse effect
on the party that is the subject of such due diligence review, or such
party's business, or such party's ability to satisfy its representations,
warranties or covenants under this Agreement, or that would impair the
ability of such party to consummate this Agreement or the transactions
contemplated hereby, then the parties hereto shall discuss such matter in
good faith and use their respective best efforts to negotiate a mutually
satisfactory solution to any differences of opinion with respect to the
materiality of such matter or matters and/or the effect that such matter or
matters is likely to have with respect to the ability of the reviewed party
or parties to consummate this Agreement and the transactions contemplated
hereby in the manner anticipated by the parties hereto, provided that if
the parties hereto are, after all such discussions and negotiations have
ended, unable to resolve their differences concerning such matter or
matters, then the reviewing party shall have the right, exerciseable in its
sole discretion, for a period of five (5) business days after such
discussions and negotiations have concluded,
29
34
to terminate this Agreement without penalty therefor, but without
prejudice to the right of the other party or parties, among other things,
to seek judicial review of, or other remedies in regard to, the
reasonableness of the terminating party or parties in regard to terminating
this Agreement; provided, however, that in the case of Ampersand and
Acquisition Sub, the right to terminate this Agreement pursuant to this
subsection shall extend only until February 28, 2001, and in the case of
AccuMed, the right to terminate this Agreement pursuant to this subsection
shall extend only until the twenty-eighth (28th) day after the date on
which Ampersand and Acquisition Sub have completed the delivery to AccuMed
of a true and correct copy of each document responsive to the due diligence
request submitted by AccuMed to Ampersand in a written memorandum dated
September 29, 2000, a copy of which Ampersand acknowledges having received
on or about such date.
(iii) In the event that any matter as described in the
immediately preceding subparagraph shall be discovered by a party after its
respective cut-off date, as set forth in said subparagraph, such party
shall thereafter have such rights with respect thereto and to the breach or
anticipatory breach of this Agreement as shall be otherwise provided
hereunder or by law.
II Conditions to Obligations of AccuMed. The obligations of AccuMed to
effect the Merger and the other transactions contemplated hereby shall be
subject to the satisfaction or written waiver by AccuMed of the following
additional conditions before the Merger Effective Time:
I No Material Adverse Effect. From and after the Execution Date,
and through and including the Merger Effective Time, neither Ampersand nor
Acquisition Sub shall have been affected by any event or change which has had or
caused a material adverse effect or material adverse change on it.
II Representations and Warranties to be True; Fulfillment of
Covenants and Conditions. (i) The representations and warranties of Ampersand
and Acquisition Sub shall be true and correct (subject to Section 2.20 hereof)
as of the Execution Date and at the Merger Effective Time with the same effect
as though made at the Merger Effective Time (or on the date when made in the
case of any representation or warranty which specifically relates to an earlier
date) except where the failure to be true and correct would not have, or would
not reasonably be expected to have, a material adverse effect, on Ampersand or
Acquisition Sub; (ii) each of Ampersand and its Subsidiaries, including
Acquisition Sub, shall have performed all obligations and complied with each
covenant, in all material respects, and satisfied all conditions under this
Agreement on its part to be satisfied at or before the Merger Effective Time;
and (iii) each of Ampersand and Acquisition Sub shall have delivered to AccuMed
a certificate, dated the Merger Effective Time and signed by its Chief Executive
Officer and President, certifying as to the satisfaction of clauses (i) and (ii)
hereof.
30
35
III No Litigation. Other than as set forth in its Disclosure
Schedules, neither Ampersand or Acquisition Sub, nor any other Ampersand
Subsidiary, shall be subject to any pending litigation which, if determined
adversely to Ampersand or any Ampersand Subsidiary, would have a material
adverse effect on Ampersand or such Subsidiary.
III Conditions to Obligations of Ampersand and Acquisition Sub. The
obligations of Ampersand and Acquisition Sub to effect the Merger and the other
transactions contemplated hereby shall be subject to the satisfaction or written
waiver by Ampersand and Acquisition Sub of the following additional conditions
before the Merger Effective Time:
I No Material Adverse Effect. From and after the Execution Date,
and through and including the Merger Effective Time, AccuMed shall not have been
affected by any event or change which has had or caused a material adverse
effect or material adverse change on AccuMed.
II Representations and Warranties to be True; Fulfillment of
Covenants and Conditions. (i) The representations and warranties of AccuMed
shall be true and correct (subject to Section 2.20 hereof) as of the Execution
Date and at the Merger Effective Time with the same effect as though made at the
Merger Effective Time (or on the date when made in the case of any
representation or warranty which specifically relates to an earlier date) except
where the failure to be true and correct would not have, or would not reasonably
be expected to have, a material adverse effect on AccuMed; (ii) AccuMed and its
Subsidiaries shall have performed all obligations and complied with each
covenant, in all material respects, and satisfied all conditions under this
Agreement on its part to be satisfied at or before the Merger Effective Time;
and (iii) AccuMed shall have delivered to Ampersand a certificate, dated the
Merger Effective Time and signed by its Chief Executive Officer and President,
certifying as to the satisfaction of clauses (i) and (ii) hereof.
III No Litigation. Other than as disclosed in its Disclosure
Schedules, neither AccuMed nor any AccuMed Subsidiary shall be subject to any
pending litigation which, if determined adversely to AccuMed or any AccuMed
Subsidiary, would have a material adverse effect on AccuMed.
IV Voting Agreements. Ampersand and Acquisition Sub shall have
received from AccuMed, substantially in the form of Exhibit A attached hereto,
the voting agreements of all officers and directors of AccuMed, as contemplated
by this Agreement.
V Employment Agreements. Prior to Closing, AccuMed shall have
terminated the employment agreements of those employees of AccuMed and/or its
Subsidiaries identified and listed by Ampersand on Exhibit D attached hereto, in
accordance with the applicable
31
36
termination provisions contained in such agreements as of the Execution Date,
or, in the absence of such provisions, upon such terms and conditions as shall
be reasonably acceptable to Ampersand and Acquisition Sub.
VI Dissenting Shares. No more than five percent (5%) of the issued
and outstanding shares of each class of AccuMed capital stock shall be
Dissenting Shares as of the final date on which such shares may become
Dissenting Shares under the DGCL.
VII Compliance with Budget Statement. A certificate shall have been
delivered by AccuMed to Ampersand, signed by AccuMed's Chief Executive Officer,
certifying that, without the prior written approval of Ampersand and Acquisition
Sub, no material expenditures of cash, other than the items set forth in the
Budget Statement, have been made or committed to by AccuMed or its Subsidiaries
during that portion of the time period covered by the Budget Statement that has
preceded the Closing.
IV Termination of Agreement.
I Methods of Termination. This Agreement may be terminated at any
time prior to the Merger Effective Time, whether before or after approval of
this Agreement by the stockholders of AccuMed or Acquisition Sub, in the
following manner:
(i) by the mutual consent, in writing, of all of the parties
hereto; or
(ii) by AccuMed, by giving written notice of such termination to
the other parties hereto if, upon the taking of the vote of AccuMed's
stockholders required by the provisions of Section 1.7(a) hereof, the required
approval of the AccuMed stockholders shall not be obtained, provided that the
Board of Directors of AccuMed recommended, and used its best efforts to obtain,
the adoption of this Agreement and approved of the transaction contemplated
hereby prior to the taking of such vote; or
(iii) by AccuMed, by giving written notice of such termination
to Ampersand and Acquisition Sub, (A) if there has been (I) a material breach of
any agreement herein on the part of Ampersand or Acquisition Sub which has not
been cured or adequate assurance of cure given, in either case within twenty
(20) calendar days following notice of such breach from AccuMed (subject,
however, to the provisions of Section 1.12(b) hereof), or (II) a breach of a
representation or warranty of Ampersand or Acquisition Sub herein which
(individually or, together with such other breaches, in the aggregate) would
reasonably be expected to materially impair the ability of Ampersand or
Acquisition Sub to perform its obligations under this Agreement and which, in
the reasonable opinion of AccuMed, by its nature cannot be cured prior to May
31, 2001, or (B) if there shall have occurred or been proposed after the date of
this Agreement (I) any change in any law, rule or regulation, or (II) there
shall have been any decision
32
37
or action by any court, government or governmental agency, that could reasonably
be expected to prevent consummation of the Merger or delay such consummation
beyond May 31, 2001, or that would have a material adverse effect on Ampersand
or Acquisition Sub; or
(iv) by Ampersand or Acquisition Sub, by giving written notice
of such termination to AccuMed, (A) if there has been (I) a material breach of
any agreement herein on the part of AccuMed which has not been cured or adequate
assurance of cure given, in either case within twenty (20) calendar days
following notice of such breach from Ampersand or Acquisition Sub, or (II) a
breach of a representation or warranty of AccuMed herein which (individually or,
together with other such breaches, in the aggregate) would reasonably be
expected to materially impair the ability of AccuMed to perform its obligations
under this Agreement and which, in the reasonable opinion of Ampersand or
Acquisition Sub, by its nature cannot be cured prior to May 31, 2001, (B) if any
Takeover Proposal (as defined in Section 3.3 hereof) with respect to AccuMed,
other than as contemplated by this Agreement, shall have been proposed by any
third party (and such proposal is not opposed in writing by AccuMed within
twenty (20) calendar days after AccuMed shall have first received or become
aware of such proposal, or AccuMed or its Board of Directors at any time shall
cease to oppose such proposal or shall take, or permit any of its Subsidiaries
to take, any action which is not consistent with opposition to such proposal),
or shall have been agreed to or consummated, or (C) if there shall have occurred
or been proposed after the Execution Date (I) any change in any law, rule or
regulation, or (II) there shall have been any decision or action by any court,
government or governmental agency, that could reasonably be expected to prevent
consummation of the Merger or delay such consummation beyond May 31, 2001, or
that would have a material adverse effect on AccuMed; or
(v) by any party, by giving written notice of such termination
to the other parties, if the Merger shall not have been consummated on or before
May 31, 2001 (or such later date as the parties hereto may, from time to time,
establish as the termination date hereof by Amendment hereto), unless the
failure of the Closing to occur by such date shall be due to the failure of the
party seeking to terminate this Agreement to perform or observe the covenants
and agreements of such party set forth herein; or
(vi) by the reviewing party or parties pursuant to the terms
and provisions of Section 4.1(i) hereof, provided that said party or parties
shall have given timely notice of such termination to the other parties hereto
in writing in accordance with the provisions of Section 7.4 hereof.
II Further Liability. If this Agreement is terminated for any
reason, none of the parties hereto shall have any further liability hereunder of
any nature whatsoever to the other parties; provided, however, that,
notwithstanding the foregoing, (i) this Section 4.4(b) shall not preclude
liability from attaching to a party who has caused the termination hereof by a
willful act or a willful failure to act in violation of the terms and provisions
hereof, and (ii) termination of this
33
38
Agreement shall not terminate or affect the agreements of the parties contained
in Section 2.7 (No Broker's or Finder's Fees), Section 3.6 (Publicity), Article
V (Termination Obligations) and Section 7.2 (Confidentiality) hereof, the
provisions of all of which shall survive any termination of this Agreement;
provided, however, that any aggrieved party, without terminating this Agreement,
shall be entitled to specifically enforce the terms hereof against the breaching
party or parties in order to cause the Merger to be consummated. Each party
hereto acknowledges that there is not an adequate remedy at law to compensate
the other parties with respect to relating to the non-consummation of the
Merger. To this end, each party, to the extent permitted by law, irrevocably
waives any defense it might have based on the adequacy of a remedy at law that
might be asserted as a bar to specific performance, injunctive relief or other
equitable relief.
III No Survival of Representations, Warranties or Agreements. The
representations, warranties and agreements set forth in this Agreement shall not
survive the Merger Effective Time and shall be terminated and extinguished at
the Merger Effective Time, and from and after the Merger Effective Time no party
hereto shall have any liability to the other parties on account of any breach or
failure of any of those representations, warranties or agreements; provided,
however, that the foregoing clause (i) shall not apply to agreements of the
parties which by their terms are intended to be performed after the Merger
Effective Time by the Surviving Corporation or otherwise, and (ii) shall not
relieve any party or person for liability for fraud, deception or intentional
misrepresentation.
ARTICLE V
TERMINATION OBLIGATIONS
I Breach by AccuMed. If this Agreement is terminated by Ampersand or
Acquisition Sub pursuant to Section 4.4(a)(iv)(B) hereof, AccuMed shall pay to
Ampersand and Acquisition Sub, jointly, the aggregate amount of $500,000
immediately upon such termination.
II Breach by Ampersand. If this Agreement is terminated by AccuMed
pursuant to Section 4.4(a)(iii)(A) hereof, Ampersand and Acquisition Sub,
jointly, shall pay to AccuMed the aggregate amount of $500,000 immediately upon
such termination.
III Tender or Exchange Offer. If any person or group of persons, other
than Ampersand or Acquisition Sub, or any of their respective affiliates, shall
commence a tender or exchange offer for ten percent (10%) or more of any class
of securities of AccuMed, or if there shall be commenced by any person or group
of persons, other than Ampersand or Acquisition Sub, or any of their respective
affiliates, of a proxy contest with respect to AccuMed, or solicitation by any
person or group of persons, other than Ampersand, Acquisition Sub, or any of
their respective affiliates, of proxies with respect to securities of AccuMed
prior to the Closing, and, as a consequence, the Merger is not approved by the
AccuMed stockholders as and in the manner
34
39
contemplated by this Agreement, and if thereafter (i) any agreement is entered
into by AccuMed to effect a merger, sale of assets or other transaction intended
to cause a change of control of AccuMed, or a tender or exchange offer is made
to the AccuMed stockholders for the same purpose, and (ii) neither Ampersand,
Acquisition Sub, nor any of their respective affiliates is a party thereto, and
(iii) the making of such agreement or the initiation of such tender or exchange
offer occurs within twelve (12) months after the latest date on which the
AccuMed Stockholders Meeting should have been held in accordance with the
provisions of Section 1.7(a) of this Agreement, AccuMed shall pay to Ampersand
and Acquisition Sub, jointly, the aggregate amount of $500,000. Such amount
shall be due at the closing of the transaction contemplated by such agreement or
tender or exchange offer. If, however, Ampersand or Acquisition Sub, or any of
their respective affiliates, is a party to such transaction, then the $500,000
provided for in this Section 5.3 will not be payable to Ampersand and
Acquisition Sub hereunder.
IV Non-Fulfillment of AccuMed Obligations. If AccuMed shall have
withdrawn, or not included in the Prospectus/Proxy Statement, the recommendation
of its Board of Directors with respect to the Merger as provided for in this
Agreement, or shall not have held the AccuMed Stockholders Meeting on, or by,
the latest date provided for in Section 1.7(a) of this Agreement and, as a
consequence, the Merger is not approved by the AccuMed stockholders as and in
the manner contemplated by this Agreement, or the Merger does not close
notwithstanding the fulfillment of all of the conditions of Section 4.2 hereof,
and if thereafter any agreement is entered into by AccuMed to effect a merger,
sale of assets or other transaction intended to cause a change of control of
AccuMed, or a tender or exchange offer for ten percent (10%) or more of any
class of securities of AccuMed is made to the AccuMed stockholders for the same
purpose, and neither Ampersand nor Acquisition Sub, nor any of their respective
affiliates, is a party thereto, and the making of such agreement or the
initiation of such tender or exchange offer occurs within twelve (12) months
after the latest date on which the AccuMed Stockholders Meeting should have been
held in accordance with the provisions of Section 1.7(a) of this Agreement,
AccuMed shall pay to Ampersand and Acquisition Sub, jointly, the aggregate
amount of $500,000. Such amount shall be due at the closing of the transaction
contemplated by such agreement, tender or exchange offer. If, however, Ampersand
or Acquisition Sub or any of their respective affiliates, is a party to such
transaction, then the $500,000 provided for in this Section 5.4 will not be
payable to Ampersand and Acquisition Sub hereunder.
V Payment of Replacement Note. The full principal amount of the
Replacement Note, together with all accrued but unpaid interest thereon, shall
become due and payable to the holder thereof immediately upon the earlier to
occur of (i) termination, for any reason, of this Agreement and the transactions
contemplated hereby, and (ii) May 31, 2001, or such later date as the parties
hereto may, from time to time, establish as the termination date hereof and
thereof by amendment hereto; provided, however, that if this Agreement is
terminated by AccuMed pursuant to the provisions of Section 4.4(a)(iii)(A)
hereof, and AccuMed becomes entitled to payment of the $500,000 amount provided
for in Section 5.2 hereof, then AccuMed shall have the right to
35
40
offset such $500,000 amount against any payments due to the holder of the
Replacement Note under this Section 5.5, and the payment of any balance
thereafter remaining due and payable under the Replacement Note shall instead
become due and payable on the sixtieth (60th) day following the date on which
the termination of this Agreement became effective.
ARTICLE VI
CERTAIN POST-MERGER AGREEMENTS
I Indemnification.
36
41
I From and after the Merger Effective Time, Ampersand and the
Surviving Corporation shall indemnify, defend and hold harmless each person who
is now, or who has been at any time before the Execution Date or who becomes
before the Merger Effective Time, an officer or director of any of the parties
hereto or any of their respective Subsidiaries (the "Indemnified Parties")
against all losses, claims, damages, costs, expenses (including reasonable
attorney's fees), liabilities, judgments or amounts that are paid in settlement
(which settlement shall require the prior written consent of Ampersand and the
Surviving Corporation, which consent shall not be unreasonably withheld) of or
in connection with any claim, action, suit, proceeding or investigation, whether
civil, criminal or administrative (each a "Claim"), in which an Indemnified
Party is, or is threatened to be made, a party based in whole or in part on or
arising in whole or in part out of the fact that such person is or was a
director or officer of any of the parties hereto or any of their respective
Subsidiaries if such Claim pertains to any matter or fact arising, existing at
or occurring before the Merger Effective Time (including, without, limitation,
the Merger and the other transactions contemplated hereby), regardless of
whether such Claim is asserted or claimed before, or at or after, the Merger
Effective Time (the "Indemnified Liabilities"), to the fullest extent permitted
under applicable state or federal law in effect as of the Execution Date or as
amended applicable to a time before the Merger Effective Time, and Ampersand or
the Surviving Corporation shall pay expenses in advance of the final disposition
of any such action or proceeding to each Indemnified Party to the fullest extent
permitted by applicable state or federal law in effect as of the Execution Date
or as amended applicable to a time before the Merger Effective Time upon receipt
of any undertaking required by applicable law. Any Indemnified Party wishing to
claim indemnification under this Section 6.1(a), upon learning of any Claim,
shall notify Ampersand and the Surviving Corporation (but the failure so to
notify Ampersand and the Surviving Corporation shall not relieve either of them
from any liability which it may have under this Section 6.1(a), except to the
extent such failure materially prejudices Ampersand or the Surviving
Corporation) and shall deliver to Ampersand and the Surviving Corporation the
undertaking, if any, required by applicable law. Ampersand and the Surviving
Corporation shall ensure, to the extent permitted under applicable law, that all
limitations of liability existing in favor of the Indemnified Parties as
provided in their respective governing entity documents, as in effect as of the
Execution Date, or allowed under applicable state or federal law as in effect as
of the Execution Date or as amended applicable to a time before the Merger
Effective Time, with respect to claims or liabilities arising from facts or
events existing or occurring before the Merger Effective Time (including,
without limitation, the transactions contemplated hereby), shall survive the
Merger.
II For a period of six (6) years from and after the Merger
Effective Time, Ampersand and the Surviving Corporation shall cause to be
maintained in effect the current policies of directors' and officers' liability
insurance (if any) maintained by AccuMed and its Subsidiaries (provided that
they may substitute therefor policies from financially capable insurers of at
least the same coverage and amounts and containing terms and conditions that are
carried by
37
42
Ampersand and its Subsidiaries in the ordinary course of business) with respect
to claims arising from facts or events which occurred before the Merger
Effective Time.
III The obligations of Ampersand and the Surviving Corporation
provided under paragraphs (a) and (b) of this Section 6.1 are intended to be
enforceable against Ampersand and the Surviving Corporation directly by the
Indemnified Parties and shall be binding on all respective successors and
permitted assigns of Ampersand and the Surviving Corporation.
ARTICLE VII
GENERAL
I Amendments. Subject to applicable law, this Agreement may be amended,
whether before or after any stockholder approval hereof, by an agreement in
writing executed in the same manner as this Agreement and authorized or ratified
by the Boards of Directors of the parties hereto, provided that after the
approval of this Agreement by the stockholders of either AccuMed or Acquisition
Sub, no such amendment may change the amount or form of the consideration to be
delivered hereunder pursuant to Section 1.3 hereof without the further approval
of such stockholders.
II Confidentiality. All information disclosed by any party hereunder or
in connection herewith, whether prior or subsequent to the date of this
Agreement, including, without limitation, any information obtained pursuant to
Section 3.1 hereof, shall be kept confidential by the person receiving such
information and shall not be used by such person otherwise than as herein
contemplated, all in accordance with the terms of Paragraph 13 of that certain
Confidential Term Sheet (the "Term Sheet") between Ampersand and AccuMed, dated
September 22, 2000, which confidentiality terms the parties hereto acknowledge
and agree shall have a continuing, binding effect notwithstanding the
termination of all other provisions of said Term Sheet. In the event of the
termination of this Agreement, each party hereto shall use all reasonable
efforts to return, upon request, to the other parties hereto all documents (and
reproductions thereof) received from such other parties (and, in the case of
reproductions, all such reproductions) that include information subject to the
confidentiality requirements set forth above in this Section 7.2 and the Term
Sheet.
III Governing Law. This Agreement and the legal relations among the
parties hereto shall be governed by and construed in accordance with the laws of
the State of Illinois, without taking into account any provisions regarding
choice of law, except to the extent certain matters may be governed by federal
law by reason of preemption.
IV Notices. Any notices or other communications required or permitted
hereunder shall be sufficiently given if it is in writing and either personally
served, sent by confirmed
38
43
facsimile transmission, air courier guaranteeing next business day delivery or
certified or registered United States mail, postage prepaid, and shall be deemed
delivered upon receipt if personally served, or upon confirmation of receipt if
sent by facsimile transmission, or the next business day, if sent by air courier
guaranteeing next business day delivery, or, if sent by mail, there (3) business
days after deposit in the United States mail with postage prepaid and properly
addressed. For purposes hereof, the addresses of the parties hereto shall be as
follows:
If to AccuMed, to
AccuMed International, Inc.
000 Xxxxx Xxxxxxxx Xxxxxx
Xxxxx 000
Xxxxxxx, Xxxxxxxx 00000
Attention: Xxxx X. Xxxxxxxx,
Chairman of the Board and Chief Executive Officer
Telecopier: (000) 000-0000
Confirmation: (000) 000-0000
with a copy to:
Xxxxx X. Xxxxxxx, Esq.
0000 0xx Xxxxxx
Xxxxxxxxxx, Xxxxxxxxxx 00000
Telecopier: (000) 000-0000
Confirmation: (000) 000-0000
If to Ampersand or Acquisition Sub, to
Ampersand Medical Corporation
(or AccuMed Acquisition Corp., as the case may be)
000 Xxxxx Xxxxxxx
Xxxxx 000
Xxxxxxx, Xxxxxxxx 00000
Attention: Xxxxx X. Xxxxxxxx,
Chairman of the Board and Chief Executive Officer
Telecopier: (000) 000-0000
Confirmation: (000-000-0000
39
44
with a copy to:
Schwartz, Cooper, Xxxxxxxxxxx & Xxxxxx, Chartered
000 Xxxxx XxXxxxx Xxxxxx
Xxxxx 0000
Xxxxxxx, Xxxxxxxx 00000
Attention: Xxxxxxx X. Xxxxxx, Esq. or
Xxxxxx X. Xxxxxxx, Esq.,
Telecopier: (000) 000-0000
Confirmation: (000) 000-0000
or to such other address as shall be furnished in writing by any party to the
others in accordance with the provisions of this Section 7.4.
V No Assignment. This Agreement may not be assigned by any party
hereto, by operation of law or otherwise, except as contemplated hereby.
VI Headings. The descriptive headings of the several Articles and
Sections of this Agreement are inserted for convenience only and do not
constitute a part of this Agreement.
VII Counterparts. This Agreement may be executed in one or more
counterparts, each of which shall constitute an original and all of which shall
be considered one and the same agreement and shall become effective when one or
more counterparts have been signed by each of the parties hereto and delivered
to the others.
VIII Construction and Interpretation. Except as the context otherwise
requires, all references herein to any state or federal regulatory agency shall
also be deemed to refer to any predecessor or successor agency, and all
references to state and federal statutes or regulations shall also be deemed to
refer to any successor statute or regulation, as amended.
IX Binding Effect. This Agreement and every representation, warranty,
covenant, agreement and provision hereof shall be binding upon and inure to the
benefit of the parties hereto and their respective heirs, legal representatives,
beneficiaries, officers, directors, stockholders, employees, agents, successors
and permitted assigns.
X Expenses. In the event that the Merger and the transactions
contemplated hereby are not consummated, each of the parties hereto shall be
responsible for its own expenses incident thereto.
XI Third Parties. The parties hereto acknowledge and agree that by
entering into this Agreement they do not intend to confer any benefits, rights,
privileges, actions or remedies on any
40
45
person or entity under any third party beneficiary theory or otherwise, except
that after the Merger Effective Time, the beneficiaries of any representations,
warranties or covenants of any of the parties hereto that survive the Merger may
enforce such representations, warranties and covenants,
XII Entire Agreement. This Agreement, including the schedules, exhibits,
certificates and other writings delivered in connection herewith, contains the
entire understanding and agreement of the parties hereto with respect to the
subject matter hereof, and supercedes all prior and contemporaneous agreements,
understandings, proposals, letters of intent, term sheets, representations,
warranties and covenants in regard thereto, except as otherwise stated herein.
XIII Waivers. Any term or provision of this Agreement may be waived, or
the time for its performance may be extended by the party or parties entitled to
the benefit thereof. Any such waiver shall be validly and sufficiently given for
the purposes of this Agreement if, as to any party, it is in writing and signed
by an authorized representative of such party. The failure of any party hereto
to enforce at any time any provision of this Agreement shall not be construed to
be a waiver of such provision, nor in any way to affect the validity of such
provision. No waiver of any breach of this Agreement shall be held to constitute
a waiver of any other or subsequent breach.
XIV Partial Invalidity. Wherever possible, each provision hereof shall be
interpreted in such manner as to be effective and valid under applicable law,
but in case any one or more of the provisions contained herein shall, for any
reason, be held to be invalid, illegal or unenforceable in any respect, such
provision shall be ineffective to the extent, but only to the extent, of such
invalidity, illegality or unenforceability without invalidating the remainder of
such provision or provisions or any other provisions hereof, unless such a
construction would be unreasonable.
[Signature Page Follows]
41
46
IN WITNESS WHEREOF, each party has caused this Agreement to be executed
on its behalf by its duly authorized officer as of the date first hereinabove
set forth.
ACCUMED INTERNATIONAL, INC. AMPERSAND CORPORATION
By: /s/ Xxxx X. Xxxxxxxx By: /s/ Xxxxx X. Xxxxxxxx
---------------------------------- ----------------------------
Xxxx X. Xxxxxxxx, Xxxxx X. Xxxxxxxx,
Chairman of the Board Chairman of the Board
and Chief Executive Officer and Chief Executive Officer
ACCUMED ACQUISITION CORP.
By: /s/ Xxxxx X. Xxxxxxxx
------------------------
Xxxxx X. Xxxxxxxx,
President
42
47
EXHIBIT A
As of February 5, 2001
Ampersand Medical Corporation
AccuMed Acquisition Corp.
000 Xxxxx Xxxxxxx
Xxxxx 000
Xxxxxxx, Xxxxxxxx 00000
Dear Sirs:
The undersigned understands that AccuMed International, Inc. ("AccuMed"),
Ampersand Medical Corporation ("Ampersand") and AccuMed Acquisition Corp.
("Acquisition Sub"), all of which are Delaware corporations, are entering into
an Agreement and Plan of Merger (the "Merger Agreement") providing for, among
other things, a merger of AccuMed with and into Acquisition Sub, a wholly-owned
subsidiary of Ampersand (the "Merger"), pursuant to which all of the outstanding
shares of common stock of AccuMed will be exchanged for shares of common stock,
$.001 par value, of Ampersand (subject to the issuance of cash in lieu of
fractional shares).
The undersigned is a stockholder of AccuMed and is entering into this
agreement to induce Ampersand and Acquisition Sub to enter into the Merger
Agreement and to consummate the transactions contemplated thereby.
The following agreement among the undersigned, Ampersand and Acquisition
Sub is hereby confirmed by the undersigned:
1. The undersigned represents, warrants and agrees that (i) Schedule I
attached hereto sets forth the number of shares of capital stock of AccuMed (the
"Shares") of which the undersigned is currently the record or beneficial owner,
and (ii) the undersigned is, as of the date hereof, the lawful owner of the
Shares set forth on Schedule I, none of which are subject to any other voting
agreements or similar restrictions, except as disclosed on Schedule I. Except as
set forth on Schedule I, the undersigned does not own or hold any rights to
acquire any additional Shares (whether by exercise of stock options, warrants,
other convertible securities, preemptive rights or otherwise), or any voting
rights with respect thereto (all of such rights and/or interests being
hereinafter collectively referred to as "Share Rights").
X-0
00
0. The undersigned agrees that the undersigned will not, and will not
permit any person or entity controlled by the undersigned to, contract to sell,
sell or otherwise transfer or dispose of any of the Shares or Share Rights
disclosed on Schedule I, or any interest therein, until after the AccuMed
Stockholders' Meeting (as defined in the Merger Agreement), other than (i)
pursuant to the Merger, or (ii) with the prior written consent of Ampersand and
Acquisition Sub, unless the purchaser thereof agrees in writing to be bound by
all of the provisions of this agreement.
3. The undersigned agrees that all of the Shares owned beneficially or of
record by the undersigned, or over which the undersigned has voting power or
control, directly or indirectly, at the record date for any meeting of
stockholders of AccuMed called to consider and vote to adopt the Merger
Agreement and/or the transactions contemplated thereby will be voted in favor
thereof.
4. The undersigned agrees to, and will cause any person or entity
controlled by the undersigned to also agree to, cooperate with Ampersand and
Acquisition Sub in connection with the Merger Agreement and the transactions
contemplated thereby. The undersigned agrees that the undersigned will not, and
will not permit any such person or entity to, directly or indirectly (including
through its officers, directors, employees, agents or other representatives),
initiate, solicit or encourage any discussions, inquiries or proposals with any
third party relating to a Takeover Proposal (as defined in the Merger
Agreement), or provide any such third party with information or assistance, or
negotiate with any such third party with respect to a Takeover Proposal, or
agree to or otherwise assist in the effectuation of any Takeover Proposal,
except as may be permitted by the Merger Agreement. Nothing contained herein is
intended to preclude the undersigned, in the undersigned's capacity as a
director and/or significant stockholder of AccuMed, from exercising any
fiduciary duties the undersigned may have with respect to a Takeover Proposal
(as defined in the Merger Agreement).
5. The undersigned represents and warrants to Ampersand and Acquisition
Sub that (i) the undersigned has all necessary power and authority to enter into
this agreement, and (ii) this agreement is the legal, valid and binding
obligation of the undersigned, enforceable against the undersigned in accordance
with its terms, except as enforceability may be limited by applicable laws
relating to bankruptcy, insolvency or creditors' rights generally and general
principles of equity.
6. The undersigned agrees that damages are an inadequate remedy for the
breach by the undersigned of any term or condition of this agreement, and that
each of Ampersand and Acquisition Sub shall be entitled to a temporary
restraining order and preliminary and permanent injunctive relief in order to
enforce the covenants contained herein.
7. This agreement will automatically terminate upon the earlier of (i)
termination of the Merger Agreement, and (ii) the Merger Effective Time (as
defined in the Merger Agreement).
A-3
49
8. This agreement may be amended, modified or supplemented at any time by
the written approval of such amendment, modification or supplement by all of the
parties hereto.
9. This agreement evidences the entire agreement among the parties hereto
with respect to the matters provided for herein, and there are no agreements,
representations or warranties with respect to the matters provided for herein
other than those set forth herein and in the Merger Agreement.
10. The parties hereto agree that if any provision of this agreement shall
under any circumstances be deemed invalid or inoperative, this agreement shall
be construed with the invalid or inoperative provisions deleted, and the rights
and obligations of the parties shall be construed and enforced accordingly.
11. This agreement may be executed in any number of counterparts, each of
which shall be deemed an original, but all of which, when taken together, shall
constitute one and the same instrument.
12. The validity, construction, enforcement and effect of this agreement
shall be governed by the laws of the State of Illinois, without regard to
conflicts of laws principles.
13. This agreement shall be binding upon and inure to the benefit of the
parties hereto and their respective legal representatives, successors and
permitted assigns.
14. Nothing in this agreement shall be construed to give Ampersand or
Acquisition Sub any rights to exercise or direct the exercise of voting power as
owner of the Shares, either beneficially or otherwise, for any purpose.
[Signature Page Follows]
A-4
50
IN WITNESS WHEREOF, the undersigned has executed this instrument as of the
date first hereinabove set forth.
-----------------------------------------
[If an Entity, Name of Entity]
-----------------------------------------
[Signature]
-----------------------------------------
[Print Name (and Title, if applicable)]
-----------------------------------------
[Mailing Address]
-----------------------------------------
Acknowledged and Agreed:
AMPERSAND MEDICAL CORPORATION
By:
-------------------------------------------------
Xxxxx X. Xxxxxxxx, Chairman of the Board
and Chief Executive Officer
ACCUMED ACQUISITION CORP.
By:
-------------------------------------------------
Xxxxx X. Xxxxxxxx, President
A-5
51
Schedule I
----------
8. Number of shares of AccuMed capital stock owned beneficially or of record
as of February 5, 2001:
Series A Convertible
Common Stock Preferred Stock
---------------- ----------
9. Number of shares of AccuMed common stock, if any, which could be acquired
upon the exercise of stock options, warrants, Series A Convertible
Preferred Stock, other convertible securities, preemptive rights or
otherwise:
X-0
00
XXXXXXX X
SECURED
PROMISSORY NOTE
$800,000.00 February 7, 0000
Xxxxxxx, Xxxxxxxx
10. FOR VALUE RECEIVED, AccuMed International, Inc. ("Maker"), whose
principal place of business is located at 000 Xxxxx Xxxxxxxx Xxxxxx,
Xxxxx 000, Xxxxxxx, Xxxxxxxx 00000, hereby promises to pay to the
order of Ampersand Medical Corporation ("Payee"), whose principal
place of business is located at 000 Xxxxx Xxxxxxx, Xxxxx 000, Xxxxxxx,
Xxxxxxxx 00000, the principal sum of EIGHT HUNDRED THOUSAND AND NO/100
DOLLARS ($800,000.00), at the place and in the manner hereinafter
provided, together with interest thereon at the rates described below.
11. Interest shall accrue on the balance of principal from time to time
unpaid under this Note prior to the Maturity Date (as hereinafter
defined) at an annual rate equal to Prime plus two and one-half
percent (2 1/2%). For purposes hereof, "Prime" shall mean the rate of
interest from time to time announced by LaSalle Bank, National
Association ("Bank"), as its Prime Rate, which is not necessarily the
Bank's lowest or most favorable rate of interest at any given time.
Interest shall be computed on the basis of a year consisting of 360
days and shall be based on the actual number of days during the period
for which interest is being charged.
12. Principal and interest under this Note shall be due and payable on the
earlier to occur of the following: (i) termination of the contemplated
merger transaction as outlined in the Merger Agreement (as such term
is defined in paragraph 4 hereof); and (ii) May 31, 2001 or such later
date as the parties to the Merger Agreement may, from time to time,
establish as the termination date of the Merger Agreement by amendment
thereto (such payment due date being hereinafter referred to as the
"Maturity Date"); provided, however, the Maturity Date shall be
automatically extended (without requiring a written amendment hereto)
to such later date, if any, as Maker and Payee agree by amendment of
the date specified in Section 4.4(a)(v) of the Merger Agreement (as
such term is hereinafter defined).
13. This Note is executed simultaneously and in conjunction with the
execution and delivery by Maker and Payee of that certain Agreement
and Plan of Merger, dated as of February 7, 2001 (the "Merger
Agreement"), pursuant to which the parties thereto have agreed to
enter into the merger described therein. This Note evidences the loan
from Payee to Maker referred to in paragraph 1.12 of the Merger
Agreement.
B-1
53
14. From and after the Maturity Date, or during any period in which an
Event of Default (as hereinafter defined) exists under this Note,
Maker shall pay interest on the balance of principal then remaining
unpaid at an annual rate (the "Default Rate") equal to Prime plus five
percent (5%). The interest accruing under this paragraph 5 shall be
immediately due and payable by Maker to the holder of this Note on
demand and shall be additional indebtedness evidenced by this Note.
15. Maker reserves the privilege, without penalty or premium therefor, to
prepay all or any part of the principal balance of this Note at any
time and from time to time upon two (2) business days prior written
notice to Payee of its intention to do so.
16. All payments and prepayments on account of the indebtedness evidenced
by this Note shall be first applied to accrued and unpaid interest on
the unpaid principal balance of this Note, and second to all other
sums then due Payee hereunder.
17. All payments of principal and interest hereunder shall be paid by
check or in coin or currency and shall be made at Payee's principal
place of business, as hereinabove set forth. Payment made by check
shall be deemed paid on the date Payee receives such check; provided,
however, that if such check is subsequently returned to Payee unpaid
due to insufficient funds or otherwise, the payment shall not be
deemed to have been made and shall continue to bear interest until
collected. If payment hereunder becomes due and payable on a Saturday,
Sunday or legal holiday under the laws of the State of Illinois, the
due date thereof shall be extended to the next succeeding business
day, and interest shall be payable thereon at the then applicable
interest rate during such extension.
18. An Event of Default shall occur hereunder if: (1) any amount payable
hereunder is not paid when due; or (2) Maker shall otherwise fail to
perform any of the promises to be performed by Maker hereunder or
under any security agreement with Payee relating thereto; or (3) Maker
or any person who is or shall become primarily or secondarily liable
for any payment hereunder, who is a natural person, dies; or (4) Maker
or any other party liable with respect to any payment hereunder, or
any guarantor or accommodation endorser or third party pledgor, shall
make any assignment for the benefit of creditors, or there shall be
commenced by or against Maker or any such party any bankruptcy,
receivership, insolvency, reorganization, dissolution or liquidation
proceedings, or there shall be the entry of any judgment, levy,
attachment, garnishment or other process, or the filing of any lien,
against any of the Collateral (as such term is defined in the Security
Agreement referred to in paragraph 12 hereof); or (5) in the opinion
of Payee, acting in good faith, there is any deterioration or
impairment of any of the Collateral, or any actual decline or
depreciation in the value or market price thereof that causes the
Collateral to become unsatisfactory as to value, and the Payee has
provided Maker with written notice describing the basis of such
opinion, and if Maker has failed, within five (5) business days after
receiving such notice to (x) provide
B-2
54
documents effectively refuting such opinion to Payee's satisfaction,
or (y) provide additional Collateral to eliminate the deficit or pay
down the indebtedness in an amount sufficient to erase such deficit;
or (6) there is a determination by Payee that a material adverse
change has occurred in the financial condition of the Maker from the
condition set forth in the most recent financial statement of Maker
furnished to Payee, or from the financial condition of the Maker most
recently disclosed to Payee in any manner; or (7) Maker shall fail to
do any commercially reasonable act necessary to preserve or maintain
the value and collectability of the Collateral; or (8) Maker shall
fail, within five (5) business days after receiving a written request
by Payee, to permit inspection by Payee (during normal business hours)
of Maker's books and records pertaining to the Collateral; or (9) any
guarantor of this Note shall discontinue or contest the validity of
such guaranty; or (10) there shall occur any material adverse event
that causes a change in the financial condition of Maker, or that
would have a material adverse effect on the business of Maker.
19. At the election of the holder hereof, whenever Maker shall be in
default as aforesaid (an "Event of Default"), and all applicable cure
periods have expired without a cure having been effected, then without
demand or notice of any kind, the entire unpaid principal amount
hereof, and all interest accrued thereon, shall become immediately due
and payable. Failure of the holder to exercise such election shall not
constitute a waiver of the right to exercise the same in the event of
any subsequent Event of Default. No holder hereof shall, by any act of
omission or commission, be deemed to waive any of its rights, remedies
or powers hereunder or otherwise unless such waiver is in writing and
signed by the holder hereof, and then only to the extent specifically
set forth therein. The rights, remedies and powers of the holder
hereof, as provided in this Note, are cumulative and concurrent, and
may be pursued singly, successively or together against Maker and any
security given at any time to secure the repayment hereof, all at the
sole discretion of the holder hereof. If any suit or action is
instituted or attorneys are employed to collect this Note or any part
thereof, Maker promises and agrees to pay all costs of collection,
including reasonable attorneys' fees and court costs.
20. Maker hereby (i) waives presentment and demand for payment, notice of
nonpayment and of dishonor, protest of dishonor, and notice of
protest; and (ii) waives any and all lack of diligence and delays in
the enforcement of the payment hereof.
21. This Note is secured by that certain Security Agreement, dated as of
the date hereof, pursuant to which Maker has pledged certain of its
assets and property, as described therein, as security for the payment
hereof.
22. This Note evidences a business loan that comes within the purview of
Section 205/4, paragraph (1)(c) of Chapter 815 of the Illinois
Compiled Statutes, as amended. Maker agrees that the obligation
evidenced by this Note is an exempted transaction under the Truth In
Lending Act, 15 U.S.C., Section 1601, et seq.
B-3
55
23. Time is of the essence hereof.
24. This Note is governed and controlled as to validity, enforcement,
interpretation, construction, effect and in all other respects by the
statutes, laws and decisions of the State of Illinois, without regard
to conflicts of laws principles. This Note may not be changed or
amended orally but only by an instrument in writing signed by the
party against whom enforcement of the change or amendment is sought.
25. This Note has been made and delivered at Chicago, Illinois and all
funds disbursed to or for the benefit of Maker will be disbursed in
Chicago, Illinois.
26. The obligations and liabilities of Maker under this Note shall be
binding upon and enforceable against Maker and its successors and
assigns. This Note shall inure to the benefit of and may be enforced
by Payee and its successors and assigns.
27. In the event one or more of the provisions contained in this Note
shall for any reason be held to be invalid, illegal or unenforceable
in any respect by a court of competent jurisdiction, such invalidity,
illegality or unenforceability shall not affect any other provision of
this Note, and this Note shall be construed as if such invalid,
illegal or unenforceable provision had never been contained herein.
Payee shall not collect a rate of interest on the principal balance
under this Note in excess of the maximum contract rate of interest
permitted by applicable law. All interest found in excess of that rate
of interest allowed and collected by Payee shall be applied to the
principal balance in such manner as to prevent the payment and
collection of interest in excess of the rate permitted by applicable
law.
IN WITNESS WHEREOF, Maker has executed this Note as of the date first
hereinabove written.
ACCUMED INTERNATIONAL, INC.
By:
-----------------------------------------
Xxxx X. Xxxxxxxx, Chairman of the Board
and Chief Executive Officer
B-4
56
EXHIBIT C
BUDGET STATEMENT
C-1
57
EXHIBIT D
LIST OF EMPLOYEES WHOSE EMPLOYMENT
AGREEMENTS WILL BE TERMINATED
1. Xxxx X. Xxxxxxxx
D-1
58
EXHIBIT E
CERTIFICATE OF DESIGNATION, PREFERENCES
AND RIGHTS OF SERIES A CONVERTIBLE
PREFERRED STOCK
OF
AMPERSAND MEDICAL CORPORATION
RESOLVED, that pursuant to the authority vested in the Board of Directors
of the Company in accordance with the provisions of its Certificate of
Incorporation, as amended, there be, and hereby is, created out of the class of
5,000,000 shares of Preferred Stock of the Company authorized in Section 4.1 of
its Certificate of Incorporation, as amended, a series of Preferred Stock of the
Company with the following voting powers, designation, preferences and relative,
participating, optional and other special rights, and qualifications,
limitations and restrictions:
1. Designation and Number of Shares.
590,197 shares of Preferred Stock are hereby designated as Series A
Convertible Preferred Stock, par value $0.01 per share (the "Series A Preferred
Stock").
2. Dividends. The Series A Preferred Stock shall not bear any dividend.
3. Redemption. The Series A Preferred Stock shall not be redeemable.
4. Liquidation.
Upon any liquidation, dissolution or winding up of the Company,
whether voluntary or involuntary ("Liquidation"), the holders of record of the
shares of the Series A Preferred Stock shall be entitled to receive, before and
in preference to any distribution or payment of assets of the Company or the
proceeds thereof that may be made or set apart for the holders of Common Stock
or any other security junior to the Series A Preferred Stock in respect of
distributions upon Liquidation out of the assets of the Company legally
available for distribution to its stockholders, an amount in cash equal to $4.50
per share (the "Stated Value") on the date fixed for distribution of assets of
the Company (the "Liquidation Preference"). If, upon such Liquidation, the
assets of the Company available for distribution to the holders of Series A
Preferred Stock and any other series of Preferred Stock then outstanding ranking
in parity with the Series A Preferred Stock upon Liquidation (the "Parity
Stock") shall be insufficient to permit payment in full to the holders of the
Series A Preferred Stock and the Parity Stock, then the entire assets and funds
of the Company legally available for distribution to such holders shall be
E-1
59
distributed ratably among the holders of the Series A Preferred Stock and the
Parity Stock based upon the relative amounts that would have been payable to the
holders of each series of Preferred Stock had there been sufficient assets and
funds to make full payment of the respective amounts due to such holders. By way
of illustration only, if 1,000,000 shares of Series A Preferred Stock were
issued and outstanding, and the Stated Value was $4.50 per share, the aggregate
Liquidation Preference of such shares would be $4,500,000. If 1,000,000 shares
of Parity Stock were also issued and outstanding at the same time, and the
Stated Value was $2.00 per share, the aggregate Liquidation Preference of such
shares would be $2,000,000. The Liquidation Preference of each of the two series
of Preferred Stock would then be added together (i.e., $4,5000,000 plus
$2,000,000 = $6,500,000) and the result would be divided into the Liquidation
Preference of each of the two series of Preferred Stock to determine the
relative percentage of the total assets and funds of the Company that would be
the aggregate Liquidation Preference of each series. The aggregate Liquidation
Preference of each series would then be divided by the number of issued and
outstanding shares of such series in order to determine the per share
Liquidation Preference. A merger or consolidation shall be considered a
Liquidation unless the holders of the Series A Preferred Stock receive
securities of the surviving corporation having rights substantially similar to
the rights of the Series A Preferred Stock and the stockholders of the Company
immediately prior to such transaction become the holders of at least a majority
in interest of the voting securities of the surviving corporation immediately
thereafter. Notwithstanding Section 7 hereof, such provision may be waived in
writing by a majority in interest of the holders of the then outstanding shares
of Series A Preferred Stock.
5. Other Series of Preferred Stock. The Company may issue, at any time
and from time to time, without the consent of the holders of the Series A
Preferred Stock, other series of Preferred Stock.
6. Conversion Rights.
Each holder of record of shares of the Series A Preferred Stock shall
have the right to convert all or any part of such holder's shares of Series A
Preferred Stock into Common Stock as follows:
(A) Each share of the Series A Preferred Stock shall be convertible,
at the option of the respective holders thereof, at any time after the date of
issuance, at the office of any transfer agent for the Series A Preferred Stock,
or if there is none, then at the office of the transfer agent for the Common
Stock, or if there is no such transfer agent, at the principal executive office
of the Company, into that number of shares of Common Stock of the Company equal
to the Stated Value divided by the conversion price in effect at the time of
conversion (the "Conversion Price"). The Conversion Price shall initially be
$10.3034. The number of shares of Common Stock into which each share of Series A
Preferred Stock is convertible is hereinafter collectively referred to as the
"Conversion Rate."
(B) During the three (3) year period commencing on March 1, 2001, if
the then current market price of the Company's Common Stock (as determined in
accordance with Paragraph 6(G)(ii) hereof) equals or exceeds $13.50, each share
of Series A Preferred Stock then
E-2
60
outstanding shall, at the option of the Company, upon giving twenty (20) days'
prior written notice to each holder of record, by virtue of such condition, and
without any action on the part of the holder thereof, be deemed automatically
converted into that number of shares of Common Stock into which the Series A
Preferred Stock would then be converted at the then effective Conversion Rate.
(C) Before any holder of Series A Preferred Stock shall be entitled to
convert the same into shares of Common Stock, such holder shall surrender the
certificate or certificates therefor, duly endorsed, or accompanied by a duly
executed stock power, at the office of the Company or of any transfer agent for
the Series A Preferred Stock, and shall give written notice to the Company at
its principal corporate office, of the election to convert the same. The Company
shall, as soon as practicable thereafter, issue and deliver at such office to
such holder of Series A Preferred Stock, a certificate or certificates for the
number of shares of Common Stock to which such holder shall be entitled as
aforesaid.
(D) All shares of Common Stock that may be issued upon conversion of
the Series A Preferred Stock will, upon issuance, be duly issued, fully paid and
nonassessable, and free from all taxes, liens, and charges with respect to the
issuance thereof. At all times that any shares of Series A Preferred Stock are
issued and outstanding, the Company shall have authorized and shall have
reserved for the purpose of issuance upon such conversion into Common Stock of
all Series A Preferred Stock, a sufficient number of shares of Common Stock to
provide for the conversion of all issued and outstanding shares of Series A
Preferred Stock at the then effective Conversion Rate.
(E) The Conversion Price shall be subject to adjustment from time to
time as follows:
(i) In case the Company shall (a) issue Common Stock as a
dividend or distribution on any class of the capital stock of the Company, (b)
split or otherwise subdivide its outstanding Common Stock, (c) combine the
outstanding Common Stock into a smaller number of shares, or (d) issue by
reclassification of its Common Stock (except in the case of a merger,
consolidation or sale of all or substantially all of the assets of the Company
as set forth in Paragraph 6(E)(ii) hereof) any shares of the capital stock of
the Company, the Conversion Price in effect on the record date for any stock
dividend or the effective date of any such other event shall be increased (or
decreased in the case of a reverse stock split) so that the holder of each share
of the Series A Preferred Stock shall thereafter be entitled to receive, upon
the conversion of such share, the number of shares of Common Stock or other
capital stock that it would own or be entitled to receive immediately after the
happening of any of the events mentioned above had such share of the Series A
Preferred Stock been converted immediately prior to the close of business on
such record date or effective date. The adjustments herein provided shall become
effective immediately following the record date for any such stock dividend or
the effective date of any such other events. There shall be no reduction in the
Conversion Price in the event that the Company pays a cash dividend.
X-0
00
(xx) In case of any reclassification or similar change of
outstanding shares of Common Stock of the Company, or in case of the
consolidation or merger of the Company with another corporation, or the
conveyance of all or substantially all of the assets of the Company in a
transaction in which holders of the Common Stock receive shares of stock or
other property, including cash, each share of the Series A Preferred Stock
shall, after such event and subject to the other rights of the Series A
Preferred Stock as set forth elsewhere herein, be convertible only into the
number of shares of stock or other securities or property, including cash, to
which a holder of the number of shares of Common Stock of the Company
deliverable upon conversion of such shares of the Series A Preferred Stock would
have been entitled to upon such reclassification, change, consolidation, merger
or conveyance had such share been converted immediately prior to the effective
date of such event.
(iii) No adjustment in the Conversion Price or the number of
shares of Common Stock into which a share of Series A Preferred Stock may be
converted shall be required unless such adjustment (plus any adjustments not
previously made by reason of this subparagraph (iii)) would require an increase
or decrease of at least 1 1/2% in the number of shares of Common Stock into
which each share of the Series A Preferred Stock is then convertible; provided,
however, that any adjustments that are not required to be made by reason of this
subparagraph (iii) shall be carried forward and taken into account in any
subsequent adjustment. All calculations and adjustments shall be made to the
nearest cent or to the nearest 1/100th of a share, as the case may be.
(iv) After each adjustment of the Conversion Price, the Company
shall promptly prepare a certificate signed by its Chairman or Chief Financial
Officer and a Secretary or Assistant Secretary setting forth the Conversion
Price as so adjusted, the number of shares of Common Stock into which the Series
A Preferred Stock may be converted, and a statement of the facts upon which such
adjustment is based, and such certificate shall forthwith be filed with the
transfer agent, if any, for the Series A Preferred Stock, and the Company shall
cause a copy of such statement to be sent by ordinary first class mail to each
holder of record of Series A Preferred Stock.
(F) The Company shall at all times reserve and keep available, out of
its authorized but unissued shares of Common Stock or out of shares of Common
Stock held in its treasury, solely for the purpose of effecting the conversion
of the shares of the Series A Preferred Stock, the full number of shares of
Common Stock deliverable upon the conversion of all shares of the Series A
Preferred Stock from time to time outstanding. The Company shall from time to
time in accordance with Delaware law take all steps necessary to increase the
authorized amount of its Common Stock if at any time the authorized number of
shares of Common Stock remaining unissued shall not be sufficient to permit the
conversion of all of the shares of the Series A Preferred Stock.
(G) (i) No fractional shares or scrip representing fractional shares
of Common Stock shall be issued upon the conversion of the Series A Preferred
Stock. In lieu of any fractional shares to which a holder would otherwise be
entitled, the Company shall pay cash,
E-4
62
equal to such fraction multiplied by the then current market price per share of
the Common Stock (as determined in accordance with the provisions of Paragraph
6(G)(ii) hereof) on the date of conversion.
(ii) For the purposes of any computation under this Paragraph 6,
the current market price per share of Common Stock on any date shall be deemed
to be the average of the closing prices for the twenty (20) consecutive trading
days commencing forty-five (45) business days before the day in question. The
closing price for each day shall be the last reported sales price regular way,
or, in case no sale takes place on such day, the average of the closing high bid
and low asked prices regular way, in either case (a) as officially quoted on the
principal United States market for the Common Stock, as determined by the Board
of Directors of the Company, or b) if, in the reasonable judgment of the Board
of Directors of the Company, there exists no principal United States market for
the Common Stock, then as reasonably determined by the Board of Directors of the
Company.
(H) The Company will pay any taxes that may be payable with respect to
any issuance or delivery of shares of Common Stock upon conversion of shares of
the Series A Preferred Stock. However, the Company shall not be required to pay
any tax that may be payable with respect to any transfer of any shares of the
Series A Preferred Stock or any shares of Common Stock issued as a consequence
of a conversion hereunder, and no such transfer shall be made unless and until
the person requesting such transfer has paid to the Company the amount of any
such tax, or has established, to the satisfaction of the Company, that such tax
has been paid or that no such tax is payable..
(I) The Company will not, by amendment of its Certificate of
Incorporation, as amended, or through any reorganization, recapitalization,
transfer of assets, consolidation, merger, dissolution, issuance or sale of
securities or any other voluntary action, avoid or seek to avoid the observance
or performance of any of the terms to be observed or performed hereunder by the
Company, but will at all times in good faith assist in the carrying out of all
the provisions of this Paragraph 6 and in the taking of all such action as may
be necessary or appropriate in order to protect the conversion rights of the
holders of the Series A Preferred Stock against impairment.
(J) For purposes of this Paragraph 6, any and all conversions shall be
deemed to have been made immediately prior to the close of business on the date
of surrender of the shares of Series A Preferred Stock to be converted, and the
former holder of such shares of Series A Preferred Stock, or such holder's
designee, shall be treated for all purposes as the record holder or holders of
such shares of Common Stock as of such date.
7. Voting Rights. The holders of the Series A Preferred Stock shall have
no right to vote for any purpose, except as specifically required by the General
Corporation Law of the State of Delaware and except as follows:
E-5
63
(A) So long as any shares of the Series A Preferred Stock remain
outstanding, the affirmative vote of the holders of a majority of the then
outstanding shares of Series A Preferred Stock, voting as one class together
with any other series of the Company's Preferred Stock then entitled to vote on
such matter, regardless of series, either expressed in writing or at a meeting
called for that purpose, shall be necessary to repeal, amend or otherwise change
this Certificate of Designation, Preferences and Rights or the Certificate of
Incorporation of the Company in a manner which would alter or change the powers,
preferences or rights of the Series A Preferred Stock so as to adversely affect
the Series A Preferred Stock. However, in case the Series A Preferred Stock
would be affected by any action referred to in this Paragraph 7(A) in a
different manner than any other series of Preferred Stock then outstanding, the
holders of the shares of the Series A Preferred Stock shall be entitled to vote
as a single and separate class, and the Company shall not take such action
without the affirmative vote, as above provided, of at least a majority of the
total number of shares of the Series A Preferred Stock then outstanding, in
addition to or as a specific part of the consent or affirmative vote hereinabove
otherwise required.
(B) Each share of the Series A Preferred Stock shall entitle the
holder thereof to one vote on all matters to be voted on by the holders of the
Series A Preferred Stock, as set forth above. However, if the Series A Preferred
Stock is entitled to vote together with the holders of Common Stock as one
class, then each share of Series A Preferred Stock shall entitle the holder
thereof to the number of votes per share that equals the number of whole shares
of Common Stock into which each such share of Series A Preferred Stock is then
convertible, calculated to the nearest whole share.
8. Miscellaneous.
(A) All shares of the Series A Preferred Stock purchased or otherwise
acquired by the Company or surrendered to it for conversion into Common Stock as
provided above shall be cancelled and shall be restored to the status of
authorized but unissued Preferred Stock of the Company.
(B) There shall be no sinking fund with respect to the Series A
Preferred Stock.
(C) The shares of the Series A Preferred Stock shall not have any
preferences, voting powers or relative, participating, optional, preemptive or
other special rights except as set forth above in this Certificate of
Designation, Preferences and Rights and in the Certificate of Incorporation of
the Company, as amended.
(D) The holders of record of shares of the Series A Preferred Stock
shall be entitled to receive all communications sent by the Company to the
holders of the Common Stock, sent by regular U.S. mail to such holder's address
as set forth in the records of the registrar for the Series A Preferred Stock.
E-6
64
IN WITNESS WHEREOF, Ampersand Medical Corporation. has caused this
Certificate to be signed by Xxxxx X. Xxxxxxxx, its Chairman of the Board and
Chief Executive Officer, on February 7, 2001, and such person hereby affirms
under penalty of perjury that this Certificate is the act and deed of Ampersand
Medical Corporation and that the facts stated herein are true and correct.
AMPERSAND MEDICAL CORPORATION
By:
--------------------------------------------
Xxxxx X. Xxxxxxxx, Chairman of the Board
and Chief Executive Officer
E-7
65
EXHIBIT F
REVISED BUDGET STATEMENT
F-1
